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“In times of great change (which is always), 
learners inherit the earth, while the learned find 
themselves beautifully  equipped for a world that 
no longer exists.”
Eric Hoffer (1902 - 1983), philosopher
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ABSTRACT
Recenti studi condotti su modelli di topi transgenici hanno evidenziato che nei 
mammiferi la regolazione delle dimensioni di un organo è controllata dalla cascata 
chinasica Hippo pathway, che sopprime la crescita antagonizzando il co-attivatore 
trascrizionale Yes-associated protein (YAP). Lo scopo di questo studio è stato quello di 
indagare se: la Hippo pathway gioca un ruolo critico nell’arresto della crescita del 
fegato indotta dalla somministrazione di dosi ripetute del mitogeno 1,4-bis[2-(3,5-
dicloropiridilossi)]benzene (TCPOBOP), un’agonista del recettore nucleare constitutive 
androstane receptor (CAR); la disregolazione di questa pathway è coinvolta nello 
sviluppo dell’epatocarcinoma (HCC), indotto in seguito al trattamento con una singola 
dose di dietilnitrosamina (DENA) e seguito dalla somministrazione di dosi ripetute del 
TCPOBOP. I risultati di questo studio hanno dimostrato che la risposta iperplasica del 
fegato in seguito al trattamento con una singola dose di TCPOBOP, evidenziata 
dall’aumentata incorporazione della bromodeossiuridina (BrdU) e dall’incremento della 
proteina proliferating cell nuclear antigen (PCNA), è associata ad un notevole 
incremento dei livelli proteici del co-attivatore YAP e dei livelli dell’mRNA del suo 
gene target, baculoviral inhibitor of apoptosis repeat-containing 5 (Birc5/survivin). Al 
contrario, la somministrazione di una seconda dose di TCPOBOP, non causa né 
un’ulteriore crescita della massa epatica, né un’aumento dei livelli proteici dello YAP, 
suggerendo che la Hippo pathway è coinvolta nella refrattarietà del fegato agli ulteriori 
stimoli mitogenici. Negli epatocarcinomi sviluppati nei topi sottoposti al trattamento 
DENA + TCPOBOP è stata osservata l’overespressione e la traslocazione nucleare dello 
YAP. L’incremento nell’espressione dello YAP negli epatocarcinomi è risultato essere 
accompagnato dall’overespressione dei livelli dell’mRNA per l’alfa-fetoprotein (AFP) e 
il connective tissue growth factor (CTGF), riconosciuti come geni target dello YAP, e da 
una significativa down-regolazione del miRNA-375. Su questi basi i presenti dati 
suggeriscono che la Hippo pathway svolge un ruolo critico nella regolazione 
dell’accrescimento del fegato indotto da TCPOBOP, consentendoci di ipotizzare che 
questa cascata chinasica probabilmente non risulta più attiva nelle cellule tumorali che, 
pertanto, diventano resistenti all’effetto soppressivo sulla crescita, che si può osservare 
nel tessuto normale circostante, e si espandono clonalmente fino a formare HCCs.
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Chapter 1
Introduction
1.1 - Background
How multicellular organisms orchestrate the growth of their individual cells and 
eventually the size of the respective organs is a primary question that has drawn the 
attention and interest of entire generations of biologists. In the past decade, much has 
been learned about tissue growth control, but  it is evident that the comprehension of this 
process is far from complete.
The liver is an interesting organ which in adult organisms is in a quiescent state but 
under certain conditions shows a remarkable regenerative capacity. In fact, following a 
2/3 surgical resection, most of the liver size is regained within 3 to 4 days (Higgins and 
Anderson, 1931). After the initial growth, no further enlargement of the liver is 
observed, suggesting the existence of pathways leading to termination of liver 
regeneration. While some studies have initially proposed transforming growth factor-
beta (TGF-β) as the terminator of liver regeneration (Michalopoulos, 2007), given its 
mitoinhibitory properties and its upregulated expression as regeneration progresses, no 
clear evidence has ever been achieved. Moreover, it  is unknown how the liver senses 
this termination signal or what the underlying mechanism/s involved is/are. 
Even more striking is the capacity of the liver to modify  its size in response to 
physiologic stimuli (such as hepatic enlargement during pregnancy) or in response to 
xenobiotics with mitogenic potency. Many  xenobiotics able to induce liver enlargement 
are ligands of the nuclear receptor superfamily and interestingly are also non-genotoxic 
liver carcinogens (Germain et al., 2006). In spite of several studies, the key molecular 
events which govern the tumoral potency  of ligands of nuclear receptors are still 
unclear. The breakthrough that many compounds which possess liver tumor promoting 
ability  are also potent inducers of hepatocyte proliferation led to the supposition that the 
mechanisms by which these agents cause liver neoplasia are a consequence of their 
mitogenic capacity  that ultimately  results in an increased rate of mutation (Marsman et 
al., 1988; Ames and Gold, 1990). However, it can be hypothesised that tumors arising in 
these enlarged livers may be the consequence of the ‘escape’ of ‘selected’ cells from the 
regulatory mechanism/s governing the size of the organ.
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Accumulating evidence suggests that a ‘size checkpoint’ operates at the level of the 
organ’s total mass, rather than on the size or number of the constituent cells. 
Coordination of cell proliferation and death is essential not only to attain proper organ 
size during development, but also for maintaining tissue homeostasis throughout 
postnatal life. In Drosophila, these two processes are orchestrated by the Hippo kinase 
cascade, a growth suppressive pathway that ultimately  antagonizes the transcriptional 
coactivator Yorkie (Yki). Components of the Hippo pathway, known to be crucial in 
control of organ size are highly conserved in mammals (for review, Edgar, 2006). 
Genetic and biochemical studies gradually structured the current model, in which the 
mammalian sterile-20-like kinase 1/2 (Mst1/2) interact with the WW domain-containing 
adapter protein (WW45) to phosphorylate and activate the large tumor suppressor 
kinase 1/2 (Lats1/2) (Chan et al., 2005; Callus et al., 2006). Lats1/2 kinase is also 
activated by the Mps one binder kinase activator protein (Mob1) (Praskova et al., 2008). 
Subsequently, Lats1/2 directly phosphorylate, hence inactivate via cytoplasmic 
sequestration the transcriptional coactivator Yes-associated protein (YAP, mammalian 
homolog of Yki) (Zhao et al., 2007; Hao et al., 2008). Dysregulation of the Hippo 
pathway results in YAP dephosphorylation, thus its activation (through loss of the 
kinase cascade), leading to nuclear translocation where it binds to transcription factor/s 
and regulates the transcription of this pathway’s target genes (Zhao et al., 2008). 
It has been reported, using conditional YAP transgenic mouse models, that  YAP induces 
a dramatic increase in liver size and eventually leads to hepatocellular carcinoma (HCC) 
formation, its overexpression phenocopying the loss of the Hippo pathway components 
(Camargo et al., 2007; Dong et al., 2007), related to organ size control.
Chapter 1                                                                                                                                      Introduction
3
1.2 - Direct hyperplasia
In the past two decades a vast number of agents were identified to be able to directly 
stimulate hepatocyte proliferation in the absence of cell loss. This hepatic proliferation 
induced by such agents, termed direct mitogens, was denominated as direct hyperplasia 
(Columbano and Shinozuka, 1996). Such replicative modality leads to an increase of 
hepatocyte DNA synthesis resulting in a significant liver mass growth within 2-3 days. 
The potency  of the mitogenic stimulus and the peaks of the S phase vary according to 
the nature of the agents (Columbano et al., 2003). These direct  mitogens include a broad 
spectrum of chemicals with little structural similarity such as peroxisome proliferators 
(PPs), retinoic acids (RAs), triiodothyronine (T3) and the halogenated hydrocarbon 1,4-
bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) (for review, Columbano and 
Shinozuka, 1996). 
Mitogen/s Receptor/s
Peroxisome Proliferators Peroxisome Proliferator Activated Receptors
Retinoic Acids Retinoic Acid Receptors
Triiodothyronine Thyroid Hormone Receptors
Halogenated Hydrocarbons Constitutive Androstane Receptor
Table 1  The main mitogens and their respective receptor/s, through which they induce 
direct hyperplasia.
1.2.1 - Nuclear receptor superfamily
The above mentioned mitogens are all ligands of different receptors belonging to the 
nuclear receptor superfamily, namely  the peroxisome proliferator activated receptors 
(PPARs), retinoic acid receptors (RARs), thyroid hormone receptors (TRs) and 
constitutive androstane receptor (CAR) (Mangelsdorf et al., 1995; Tzameli et al., 2000). 
Subsequent to the activation by the respective ligands these receptors act as 
transcription factors. In fact, following the binding with the respective ligands, PPARs, 
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RARs, TRs and CAR homodimerize or heterodimerize with 9-cis-retinoic acid receptor 
(RXR), forming transcriptional active dimers which are able to bind to specific elements 
of the DNA, made up of an AGGTCA nucleotide sequence (Kliewer et al., 1992). Once 
bound to the DNA, the dimers directly regulate the expression of target genes 
implicated in lipid metabolism, cell differentiation, cell proliferation and xenobiotic 
metabolism or act through cross-talking with other signal transduction pathways 
(Aranda and Pascual, 2001). The transcriptional activity of these nuclear receptors is 
regulated through the recruitment  of corepressor and coactivator proteins. Corepressors 
constitute various multiprotein complexes which have a deacetylase activity. This 
deacetylation increases the density of chromatin leading to the repression of 
transcription. On the contrary, following ligand binding, the receptors undergo a 
transconformational change which allow the recruitment of coactivators. Some of these 
proteins are chromatin remodeling factors which hold acetylase histone activity, while 
others can act directly with the transcriptional machinery. Recruitment of coactivator 
complexes by the promoter target cause chromatin decondensation and subsequently 
induce transcriptional activity. The characterization of corepressors and coactivators, 
together with the identification of the domains through which they interact specifically 
with the receptor, has demonstrated the existence of a molecular mechanism by  which 
these receptors bring about their transcriptional action on target genes (McKenna et al., 
1999; Xu et al., 1999; Dilworth and Chambon, 2001).
1.2.1.1 - CAR
This receptor, highly expressed in the liver, is active in the absence of ligand with the 
unique capability to be further regulated by activators. CAR is compartmentalized in the 
cytoplasm in a similar manner to other nuclear receptors (Kawamoto et al., 1999). 
Retention in the cytoplasm prevents chronic activation of its target genes and allows 
tight regulation of the receptor’s activity. Two endogenous ligands, androstenol and 
androstanol (both metabolites of androstane), interact directly with CAR to repress its 
constitutive activity  (Forman et al., 1998). Activators (mainly  drugs and xenobiotics) 
either bind directly to CAR, consistent with other family members, or act  indirectly, 
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such as phenobarbital (PB), which do not bind to the receptor but translocate CAR to 
the nucleus, making translocation an initial step  in the CAR activation process 
(Kawamoto et al., 1999; Zelko et al., 2001). A phosphorylation cascade is involved in 
regulating CAR translocation, yet elucidation of the CAR activation mechanism has 
proved difficult due to the fact that CAR accumulates spontaneously in the nucleus of 
transformed cell lines regardless of activation state (Kawamoto et al., 1999). A protein 
capable of retaining CAR in the cytoplasm of transformed cell lines has now been 
identified, facilitating the elucidation of the exact activation mechanism hopefully  in the 
near future (Kobayashi et al., 2003). Moreover, it has become apparent that 
translocation alone does not  determine CAR activation, but that additional regulation is 
required in the nucleus (Fig. 1). 
of a single amino acid residue in CAR is able to alter
a given specificity. Mutation of Thr350 in hormone-
responsive mouse CAR to methionine, as in nonre-
sponsive human CAR, could abolish the repression by
testosterone and progesterone and reactivation by es-
trogen (69). However, mutation of this residue did not
change the repression of CAR activity by Ca2!/cal-
modulin kinase inhibitor KN62, suggesting that the
structural basis for hormone repression differs from
that for repression by xenochemicals (69). In support
of this hypothesis, only mutation of Leu352, a pre-
dicted key residue for AF2 interaction with coactiva-
tors, could abolish responsiveness to TCPOBOP and
mutation of either residue Cys357 or Tyr336, which are
proposed to interact with and stabilize helix 12, abol-
ished the repressive effect of androstanol on transcrip-
tional activity (70). Thus it appears that diverse CAR
ligands interact with different residues to exert their
effects, corresponding to the receptor’s large LB cav-
ity and predictions of alternate LB orientations (48, 60,
61). Four naturally occurring in-frame splice variants of
the human CAR gene compromise DNA binding, co-
activator recruitment, and transcriptional activation,
providing an additional source for functional variability
and possible alternate interaction sites for those acti-
vators unable to bind directly to wild-type CAR (71).
This promiscuous nature is reminiscent of CYP en-
zymes that exhibit broad substrate specificity yet de-
termine a given activity by a single amino acid residue
(72, 73). However, CAR is unique in the sense that
activators do not necessarily directly bind to regulate
CAR.
NUCLEAR TRANSLOCATION MECHANISM
Ligand-Independent Translocation
CAR is retained in the cytoplasm of untreated cells and
translocates into the nuclei of liver cells after treatment
Fig. 2. Mechanism of CAR Activation
CAR translocation can be triggered by either direct ligand binding to the receptor, or indirectly, via a partially elucidated signal
transduction pathway. CAR exists in a complex with Hsp90, retained in the cytoplasm by the cochaperone CCRP. Indirect
activators or the direct binding of ligands to CAR subsequently recruits PP2A to the complex. Once in the nucleus, further
activation steps involving calmodulin-dependent kinase and recruitment of coactivators occur before DNA binding and tran-
scriptional activation of target genes.
Swales and Negishi • Minireview Mol Endocrinol, July 2004, 18(7):1589–1598 1593
Fig. 1  CAR translocation an be induced by  e ther dire t ligand binding to the receptor, 
or indirectly, via a partially elucidated signal transduction pathway. CAR exists in a 
complex with heat shock protein 90 (Hsp90), retained in the cytoplasm by the 
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cochaperone cytoplasmic CAR retention protein (CCRP). Indirect activators or the 
direct binding of ligands to CAR subsequently  recruits protein phosphatase 2A (PP2A) 
to the complex. Once in the nucleus, further activation steps involving calmodulin-
dependent kinase and recruitment of coactivators occur before DNA binding and 
transcriptional activation of target genes (Swales and Negishi, 2004).
CAR has been identified as a mediator of the induction of cytochrome P450 (CYP) gene 
expression, especially  cytochrome P450, family 2, subfamily b, polypeptide 10 
(Cyp2b10) in response to a particular class of xenobiotic compounds (Honkakoski et al., 
1998a; Honkakoski et al., 1998b; Sueyoshi et al., 1999). These chemicals, exemplified 
by PB, markedly increase expression of this CYP enzyme and other proteins involved in 
metabolism and thus elimination of drugs and other xenobiotic compounds (Wei et al., 
2000; Maglich et al., 2002; Ueda et al., 2002; Wei et al., 2002; Honkakoski et al., 2003; 
Rosenfeld et al., 2003). Although they do not share any apparent chemical similarities, 
these compounds are collectively referred to as ‘PB-like’ inducers, on the basis of their 
similar biological responses. The most potent of these xenobiotics, originally isolated as 
a pesticide contaminant (Poland et al., 1980), is TCPOBOP. Even quite low 
concentrations of this xenobiotic agent efficiently activate CYP gene expression in mice 
(Poland et al., 1980; Poland et al., 1981; Raunio et al., 1988; Kelly  et al., 1990; Diwan 
et al., 1992; Smith et al., 1993). Perhaps the simplest of several possible mechanisms to 
account for the effects of TCPOBOP is that it  acts as an agonist ligand for CAR, 
resulting directly in Cyp2b10 gene activation. This mechanism has been strongly 
supported by results that are the mirror image of those obtained with the inverse 
agonists (Tzameli et al., 2000). Thus, binding of TCPOBOP significantly increases 
coactivator recruitment by CAR, both in vitro and in vivo.
1.2.1.1.1 - TCPOBOP
TCPOBOP is the most potent CAR agonist, with respect to other drugs and xenobiotics 
(including PB), reported to induce liver hyperplasia and hypertrophy  in mice (Dragani 
et al., 1985; Manenti et al., 1987). Similar to other xenobiotics, this hepatic mitogen 
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achieves such effect by accelerating the entry of hepatocytes into the S phase of the cell 
cycle (Ledda-Columbano et al., 2000). A single administration of TCPOBOP is much 
more effective in inducing hepatocyte proliferation in females than in males (Ledda-
Columbano et al., 2003). Such proliferative response remains efficient during all adult 
life (Ledda-Columbano et al., 2004). Moreover, TCPOBOP given chronically was 
found to be a non-genotoxic hepatocarcinogen. In addition, it is reported to be the most 
powerful liver tumor promoter, when compared to other drugs and xenobiotics 
(comprising PB), by the criterion of increased numbers of diethylnitrosamine (DENA)-
initiated preneoplastic foci in mice (Dragani et al., 1985; Diwan et al., 1986; Romano et 
al., 1986; Dragani et al., 1987; Diwan et al., 1988; Diwan et al., 1992). TCPOBOP 
results in a high percentage of liver tumor metastases to the lung, implying effects on 
tumor progression. Although TCPOBOP does not cause liver tumor promotion in rats, it 
does increase the incidence of nasal cavity tumors in DENA-treated rats but not mice 
(Diwan et al., 1992).
1.3 - Hippo signaling pathway
Meticulous control of cell proliferation and death is crucial for attaining correct organ 
size during development but also for maintaining proper organ regeneration. Such 
process is an essential function of multicellular organisms under physiological 
conditions.  Impairment of this function frequently leads to tumorigenesis (Conlon and 
Raff, 1999). Signaling pathways transmitting extra and intracellular signals leading 
ultimately  to gene transcription are at the core of organ size regulation studies. Initial 
studies in Drosophila and more recent ones in mammals have demonstrated the 
fundamental role of the Hippo signaling pathway in controlling organ size by regulating 
not only  cell proliferation but also apoptosis. In Drosophila loss of the kinase cascade 
components lead to massive tissue overgrowth characterized by excessive cell 
proliferation and diminished apoptosis suggesting the importance of the Hippo pathway 
in organ size control (for review, Edgar, 2006). Furthermore, it was demonstrated that 
the mammalian pathway is not only implicated in the regulation of organ size but more 
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importantly that its dysregulation leads to carcinogenesis in transgenic mouse models 
(Camargo et al., 2007; Dong et al., 2007).
Fig. 2  The Hippo signaling pathway was initially described in Drosopila (left panels) 
and more recently confirmed in mammals (right panels). The Drosophila’s kinase 
cascade components are highly conserved in the mammalian signaling pathway 
(respective homologs showing the same shape and color). Hippo pathway  activation 
(upper panels) causes phosphorylation of the downstream effector Yki/YAP by Warts 
(Wts)/Lats1/2, thus bringing about its inactivation via cytoplasmic sequestration. On the 
contrary, inactivation of Hippo pathway (lower panels) results in Yki/YAP 
dephosphorylation leading to nuclear translocation where it binds to transcription 
factors/s and subsequently induces growth target genes (Buttitta and Edgar, 2007).
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1.3.1 - Drosophila
Drosophila genetic mosaic screens resulted to be a powerful tool in the elucidation of 
the Hippo signaling pathway. In the past decade, studies gradually structured the current 
model, from the core components to the downstream effectors. Recent studies showed 
that this kinase cascade functions as a regulator of organ size, signaling through 
sequential phosphorylation-mediated inactivation of the transcriptional coactivator Yki 
(Huang et al., 2005).  This function is achieved at least  in part by transcriptional 
activation of cyclin E, thread (which encodes Drosophila inhibitor of apoptosis protein 
1 (diap1)) (Wu et al., 2003) and the microRNA (miRNA) bantam (Nolo et al., 2006; 
Thompson and Cohen, 2006). Dysfunction of the Hippo pathway results in excessive 
cell proliferation and diminished apoptosis leading ultimately to massive tissue 
overgrowth. 
1.3.1.1 - Core components
The first Hippo signaling pathway component to be identified was Wts which encodes a 
nuclear dumbbell forming-2-related (NDR) family protein kinase. Wts mutation lead to 
considerable tissue overgrowth without affecting cell fate determination (Justice et al., 
1995; Xu et al., 1995). Subsequently, Salvador (Sav) encoding a WW domain-
containing adaptor protein and Hippo (Hpo) encoding a Sterile-20 (Ste-20) family 
protein kinase were identified as other components of the Hippo pathway. In this 
complex, Hpo kinase interacts directly  with the scaffold protein Sav and promotes Wts 
kinase phosphorylation (Pantalacci et al., 2003; Udan et al., 2003; Wu et al., 2003). The 
WW domain of Sav was found to mediate its binding with Wts, while the C-terminal 
domain is crucial for its interaction with Hpo (Harvey et al., 2003). Furthermore, 
Drosophila Ras-association domain family ortholog (dRASSF) was considered to 
restrict Hpo activity through competition with Sav for interaction with Hpo (Polesello et 
al., 2006). Mutation or deletion of either Sav or Hpo leads to promotion of cell 
proliferation and restriction of apoptosis resulting ultimately  in similar effects to that of 
Wts (Kango-Singh et al., 2002; Tapon et al., 2002; Harvey et al., 2003; Jia et al., 2003).
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Later on, Mats which encodes a Mob1-related protein was identified as the last core 
component of this kinase cascade. The Mats protein interacts physically with Wts as an 
activating subunit. Moreover, Mats is also phosphorylated by Hpo, enhancing the kinase 
activity of Wts in this complex. Mats mutation, like alterations of the previous 
components, lead to significant organ overgrowth through the promotion of cell 
proliferation and restriction of apoptosis (Lai et al., 2005; Wei et al., 2007; Shimizu et 
al., 2008). 
These studies converge on the main role of the Drosophila Hippo signaling pathway, 
that of restricting cell proliferation and promoting apoptosis. This function is achieved 
at least in part by transcriptional regulation of cyclin E, diap1 (Wu et al., 2003) and the 
miRNA bantam (Nolo et al., 2006; Thompson and Cohen, 2006).
1.3.1.2 - Downstream effectors
The protein levels of cyclin E and Diap1 were found to be controlled at the 
transcriptional level rather than a consequence of post translational modification of the 
proteins (Wu et al., 2003). This meant that  there should be a downstream effector that 
could carry on the message of the core components of this kinase cascade to the 
machinery  that regulates the transcription of the respective genes. The missing link was 
identified to be the transcriptional coactivator Yki, using protein interaction screening 
with Wts kinase (Huang et al., 2005). A biochemical study showed that Wts protein 
kinase directly phosphorylates Yki, amongst other (two) sites, at the crucial serine (S) 
168 residue. Phosphorylation at S168 induces Yki binding to the 14-3-3 protein, leading 
to its cytoplasmic retention and inactivation. Mutation of Yki S168 lead to the 
constitutive activation and nuclear translocation of Yki which subsequently induces the 
transcription of the Hippo pathway target genes resulting ultimately in enhanced cell 
proliferation and reduced apoptosis, hence tissue overgrowth (Dong et al., 2007, Zhang 
et al., 2008b).
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Since the transcription coactivator Yki possesses no DNA-binding activity, the next step 
was to identify target transcription factors that bring about Yki activity. Yki yeast two-
hybrid data led to the identification of Scalloped (Sd), encoding a transcriptional 
enhancer activator DNA (TEAD)-binding domain, as Yki associated transcriptional 
factor mediating Yki-induced gene expression and overgrowth phenotype (Goulev et 
al., 2008). In fact, Sd was also found to nuclearly localize and recruit  Yki to the 
promoter region of the pathway-responsive gene diap1, further confirming the latter as a 
direct transcription gene of the Hippo signaling pathway (Zhang et al., 2008b). 
Mutation of Sd abrogated proliferation and survival of wing imaginal disc cells (Wu et 
al., 2008; Zhang et al., 2008b; Zhao et al., 2008). Affinity chromatography and mass 
spectrometry  applications led to the identification of Expanded (Ex), another Yki 
associated protein. Ex binds to Yki via WW-domain-PPxY interactions, relocalizing Yki 
from the nucleus to the cytoplasm, thus withdrawing its transcriptional regulatory 
activity (Badouel et al., 2009). 
1.3.2 - Mammals
Hippo signaling pathway components are well conserved from Drosophila to mammals. 
More strikingly, the mammalian kinase cascade counterparts can substitute the function 
of their mutant homologs in Drosophila, suggesting a functional conservation of these 
components (for review, Edgar, 2006). Recent studies confirmed that the mammalian 
Hippo pathway also functions as a regulator of organ size, signaling through the same 
mechanism of action, leading to phosphorylation, thus inactivation of the transcriptional 
coactivator YAP (Dong et al., 2007). Such function is attained by transcriptional 
activation of target genes such as baculoviral inhibitor of apoptosis repeat-containing 5 
(Birc5) (Dong et al., 2007), connective tissue growth factor (CTGF) (Zhao et al., 2007) 
and alpha-fetoprotein (AFP) (Dong et al., 2007). Dysfunction of the Hippo pathway 
results not only in remarkable cell proliferation and restricted apoptosis, leading to 
immense tissue overgrowth but also in oncogenesis.
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1.3.2.1 - Core components
The highly conserved core components of the Hippo signaling pathway from 
Drosophila to mammals have been identified as Mst1/2 (Hpo homolog), WW45 (Sav 
homolog), Lats1/2 (Wts homolog) and Mob1 (Mats homolog). In this complex, Mst1/2 
play an essential role in regulating the other three components.
Mst1/2 encoding a Ste-20 family protein kinase were identified as the first components 
of the mammalian Hippo pathway. In this kinase cascade, Mst1/2 kinases assemble the 
core components and promote Lats1/2 kinases phosphorylation (Chan et al., 2005). 
Besides these central roles, Mst1/2 have been shown to interact with other components 
external to this pathway, mainly involved in apoptosis. Mst1/2 are associated with 
RASSF members (Khokhlatchev et al., 2002); RASSF1A is physically associated with 
Mst1. Initially, it was demonstrated that RASSF1A inhibits Mst1 kinase activity 
(Praskova et al., 2004).  However, a more recent study has shown that overexpression of 
RASSF1A promotes Fas-induced apoptosis via Mst1 activation (Oh et al., 2006). In 
addition, RASSF2 was found to be associated with Mst2. RASSF2 stabilizes Mst2 from 
degradation, while its deletion decreases the levels of Mst2  leading to inhibition of 
apoptosis (Cooper et al., 2009). The role of Mst2 in apoptosis was reported to be 
inhibited by the binding of Raf-1, forming an Mst2 complex which hinders its 
phosphorylation (O’Neill et al., 2004). However, stress signals can dissociate such 
complex resulting in Mst2 phosphorylation and ultimately  apoptosis (O’Neill and 
Kolch, 2005). Deletion of Mst1/2 in liver led to YAP phosphorylation inability, 
sufficient to initiate hepatocyte proliferation and resistance to apoptosis, resulting in 
dramatic liver growth and development of HCC (Zhou et al., 2009; Lu et al., 2010; 
Song et al., 2010). In spite of that, the effect of Mst1/2 deficiency on organ size is more 
substantial in certain organs (e.g. liver and stomach), than in others (e.g. kidney), which 
do not manifest such repercussions at  all (Song et al., 2010). This is due to the probable 
difference, from one organ to another, in the contribution of impaired cell differentiation 
versus cell number on the overall size of the organ. Likewise, the role of Mst1/2 in this 
pathway is presumably  to be cell context-dependent, since Mst1/2 are not necessary for 
Lats1/2 phosphorylation and for cell density-induced YAP nuclear-cytoplasmic 
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translocation in mouse embryonic fibroblast (MEF) cells, or YAP phosphorylation in 
early embryos (Zhou et al., 2009; Oh et al., 2009).
Subsequently, WW45 encoding a WW domain-containing adaptor protein was identified 
as another component of the mammalian Hippo signaling pathway. WW45 interacts 
physically with Mst1/2 through the Sav/RASSF/Hpo (SARAH) domain present in both 
proteins. WW45 can also be directly phosphorylated and stabilized by Mst1/2 (Chan et 
al., 2005; Callus et al., 2006). Recent studies, have shown that WW45 is required for 
Mst1 activation. Homozygous loss of WW45 resulted to be embryonic-lethal, with 
various organs exhibiting hyperplasia and immature differentiation in epithelium, while 
heterozygous deletion led to higher susceptibility to tumorigenesis (Lee et al., 2008). 
Moreover, it was demonstrated that suppression of WW45 hinders the already described 
Mst1-mediated apoptosis (Luo et al., 2009). In addition, conditional ablation of WW45 
in the liver resulted not only in organ size enlargement but also led to tumor formation. 
Despite that, unexpectedly, phosphorylation of Lats1/2 and YAP were not affected, 
suggesting that WW45 is not absolutely  required for the activation of Lats1/2 and can 
regulate tissue growth in the liver by some other mechanism/s (Lu et al., 2010).
Lats1/2 encoding a NDR family  protein kinase were identified as further components of 
the mammalian Hippo pathway. Lats1/2 are phosphorylated at the hydrophobic motif by 
Mst1/2, followed by the subsequent autophosphorylation of their activation loop (Chan 
et al., 2005). Deletion of Lats1 in mice resulted in higher liability to soft tissue sarcoma 
and ovarian tumor development (St John et al., 1999), while deficiency  of Lats2 
demonstrated to be embryonic-lethal (McPherson et al., 2004; Yabuta et al., 2007). 
Similarly, downregulation of Lats1 was found in human soft tissue sarcoma (Hisaoka et 
al., 2002), astrocytoma (Jiang et al., 2006) and breast cancer (Morinaga et al., 2000; 
Takahashi et al., 2005). Last1/2 are able to phosphorylate, thus inactivate YAP in vitro 
and in cell culture (Zhao et al., 2007; Hao et al., 2008). Nonetheless, it  has been 
reported that the role of Lats1/2 in YAP phosphorylation is dependent on the cell type. 
In MCF10A cells, overexpression of Lats1 solely was found to inhibit YAP-induced 
epithelial-to-mesenchymal transition (EMT), cell migration and anchorage-independent 
growth (Zhang et al., 2008a). However, deletion of both Lats1 and 2 was shown to be 
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required for an efficient inhibition of YAP phosphorylation in HeLa cells. Recent 
studies in the liver, have demonstrated contentious results regarding the necessity of 
Mst1/2 for Lats1/2 phosphorylation, even though there was a reduction in YAP 
phosphorylation (Zhou et al., 2009; Lu et al., 2010). In fact, fractionation experiments 
suggested the possibility of YAP phosphorylation by  a Mst1/2-regulated kinase different 
from Lat1/2 (Zhou et al., 2009). Nevertheless, the chance that the other NDR family 
members may phosphorylate YAP was diminished by the fact that  in vitro there is no 
NDR1/2-YAP interaction and in cell culture NDR1/2 overexpression does not induce 
YAP phosphorylation (Hao et al., 2008). Hence, Lats1/2 remain the main kinases that 
bring about YAP phosphorylation, yet the involvement of other kinases cannot be 
excluded.
Later on, Mob1 was identified as the last core component of the mammalian kinase 
cascade. Mob1 is phosphorylated by Mst1/2, which enhances the interaction between 
Mob1 and Lats1/2, eventually promoting the phosphorylation of Lats1/2 (Yabuta et al., 
2007; Hirabayashi et al., 2008; Praskova et al., 2008; Chow et al., 2010). 
Notwithstanding, the exact  mechanism of how Mob1 induces the activation of Lats1/2 
is not well comprehended. Initial studies, have established that Mob1 artificial targeting 
to plasma membrane bring about Lats1 membrane localization and the subsequent 
activation (Hergovich et al., 2006). Accordingly, Mats (Mob1 homolog in Drosophila) 
was shown to localize to plasma membrane, and this membrane-localized form, 
contrary to the wild-type protein, inhibits tissue overgrowth when overexpressed (Ho et 
al., 2009). In spite of that, endogenous Mob1 membrane localization has not been 
substantiated. Besides, the mechanism of how Mob1/Mats membrane localization is 
brought about is still not clear. A recent study in vitro, demonstrated that Mob1 in the 
presence of Mst3 activates NDR2 without having an effect  on its hydrophobic motif 
phosphorylation, suggesting another mean of NDR activation by Mob1 which could 
possibly apply to Lats1/2 activation too (Stegert et al., 2005).
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1.3.2.2 - Downstream effectors
Components of the Hippo signaling pathway so far proved to be highly conserved from 
Drosophila to mammals. This was further confirmed by the identification of the 
transcriptional coactivator YAP and its paralog transcriptional co-activator with PDZ 
binding motif (TAZ) (both Yki homologs) acting as the major downstream effectors of 
the mammalian Hippo pathway. YAP was first reported to be located on chromosome 
11q13 (Sudol et al., 1995) but later the 11q22 chromosome was also associated to this 
gene (Overholtzer et al., 2006; Zender et al., 2006). YAP has an N-terminal proline-rich 
domain, a TEAD-binding region, two WW domains (or one in the YAP1 splicing 
variant) (Sudol et al., 1995; Komuro et al., 2003), an SH3-binding motif, a coiled-coil 
domain, a transcription activation domain, and a C-terminal PDZ-binding motif. TAZ 
was found to be located on chromosome 3q24 (Kanai et al., 2000). TAZ has a similar 
domain organization to YAP, although it lacks the proline-rich domain, the second WW 
domain, and the SH3-binding motif. 
YAP functionality  was later demonstrated to depend on the presence of an intact WW 
domain/s (Yagi et al., 1999; Komuro et al., 2003).
Hpo interacts directly with Sav and promotes Sav and
Wts phosphorylation (Wu et al. 2003). Subsequently,
mats mutations were shown to phenocopy other Hippo
pathway component mutations. The Mats protein in-
teracts physically with Wts as an activating subunit (Lai
et al. 2005; Wei et al. 2007; Shimizu et al. 2008). Mats is
also phosphorylated by Hpo, resulting in increased in-
teraction with Wts. These observations have established
the core components of the Drosophila Hippo path-
way, showing the Hpo kinase—in association with Sav—
phosphorylating and activating the Wts kinase–Mats
complex (Fig. 2).
Figure 1. Domain organization and key modifications of the Hippo pathway components. The illustrations are drawn in scale unless
indicated otherwise. Human sequences are drawn unless indicated by D.m., which stands for Drosophila sequences. (CA) Cadeherin
repeats; (EGF) EGF-like domain; (LamG) Laminin G domain; (TM) transmembrane region; (WW) WW domain; (C2) C2 domain; (FERM)
FERM domain; (C1) C1 domain; (RA) Ras association domain; (SARAH) SARAH domain; (UBA) ubiquitin-associated domain; (PPXY)
PPXY motif; (HM) hydrophobic motif; (P-rich) proline-rich domain; (C-C) coiled-coil domain; (TEA) TEA DNA-binding domain.
Drosophila Fat is processed into two fragments (Feng and Irvine 2009; Sopko et al. 2009). The approximate cleavage site is indicated. Fat
cytoplasmic domain is phosphorylated by Dco (Feng and Irvine 2009; Sopko et al. 2009). Mer is phosphorylated by PAK1/2 on S518,
which affects Mer conformation and inactivates Mer as a tumor suppressor (Rong et al. 2004). Mst1 activation loop autophosphor-
ylation (T183) is essential for its kinase activity. Caspase cleavage, as indicated, activates Mst1 (Graves et al. 1998). Lats1 is activated by
autophosphorylation on the activation loop (S909), and phosphorylation by Mst1/2 on the hydrophobic motif (T1079) (Chan et al. 2005).
Mob1 is phosphorylated by Mst1/2 on T12 and T35, and this phosphorylation stimulates its interaction with Lats1/2 (Praskova et al.
2008). Sav1 is also phosphorylated by Mst1/2 on an unidentified site (Callus et al. 2006). YAP/TAZ/Yki is phosphorylated by Lats1/2 on
S61, S109, S127, S164, and S381 (TAZ S66, S89, S117, S311, Yki S111, S168, and S250) in the HXRXXS motifs (Zhao et al. 2007; Lei et al.
2008; Oh and Irvine 2008). S127 phosphorylation induces 14–3–3 binding and cytoplasmic retention (Zhao et al. 2007). S381
phosphorylation primes CK1d/e phosphorylation of S384, and S387 finally leads to SCFb-TRCP-mediated ubiquitination and degradation
(Zhao et al. 2010). YAP is also phosphorylated by c-Abl on Y391 (Levy et al. 2008).
The Hippo–YAP pathway updated
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Fig. 3  Domain organization of YAP and TAZ proteins (Zhao et al., 2010). WW domain 
(WW); proline-rich domain (P-rich); coiled-coil domain (C-C). YAP/TAZ is 
phosphorylated by Lats1/2 on S61, S109, S127, S164 and S381/S66, S89, S117, S311 in 
the HXRXXS motifs. S127/S89 phosphorylation induces 14-3-3 binding, resulting in 
cytoplasmic retention of YAP/TAZ (Basu et al., 2003; Zhao et al., 2007; Hao et al., 
2008; Lei et al., 2008).
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In fact, YAP interacts physically with Lats1/2 through the WW domain and is directly 
phosphorylated by the same Lats1/2 on five HXRXXS motifs (Zhao et al., 2007; Hao et 
al., 2008). These consensus motifs are also present in TAZ. As a matter of fact, TAZ is 
phosphorylated by  Lats1/2 on similar HXRXXS motifs (Lei et al., 2008). Furthermore, 
three of these sites are conserved and phosphorylated in Yki by  Wts (Lats1/2 homolog 
in Drosophila) (Oh and Irvine, 2009). Phosphorylation of YAP S127 and the 
corresponding site in TAZ (S89), comparable to Yki S168 phosphorylation, resulted to 
be crucial for the induction of the 14-3-3 protein binding, leading to YAP/TAZ/Yki 
cytoplasmic retention, hence their spatial separation from nuclear target transcription 
factors and gene promoters (Basu et al., 2003; Zhao et al., 2007; Hao et al., 2008; Lei et 
al., 2008; Oh and Irvine, 2008; Ren et al., 2009). 
YAP/TAZ were found to inherit the conserved functions of Yki. Overexpression of 
YAP/TAZ can stimulate cell proliferation and suppress apoptosis by  overcoming cell 
contact inhibition in cell culture. Moreover, YAP/TAZ can induce cell malignant 
transformation and promote EMT (associated with metastasis) in vitro (Overholtzer et 
al., 2006; Zhao et al., 2007, Camargo et al., 2007; Lei et al., 2008). In addition, YAP 
overexpression causes a dramatic increase in liver size and ultimately leads to tumor 
growth (Camargo et al., 2007; Dong et al., 2007). In vitro and in vivo experiments 
demonstrated that these functions of YAP/TAZ are tightly controlled by phosphorylation 
at the S127 and S381/S89 sites (Zhao et al., 2009; Chan et al., 2009). Mst1/2 and 
Lats1/2 were shown to inhibit YAP-mediated phenotypic changes through 
phosphorylation of the Hippo-responsive S sites of YAP. Mutation of these key Ss can 
rescue YAP/TAZ from phosphorylation, thus inactivation by  Mst1/2 and Lats1/2 
(Camargo et al., 2007; Zhao et al., 2007; Hao et al., 2008; Lei et al., 2008). 
Lacking a DNA-binding domain, the transcriptional coactivators YAP/TAZ have to be 
brought to gene promoters by target transcription factors. Recent studies have 
established the TEAD protein family (composed of four members) as the key 
transcription factor target of YAP/TAZ which mediates their functions (Zhao et al., 
2008; Zhang et al., 2009; Chan et al., 2009). Hence, in conformity  to the Drosophila 
homolog Sd in bringing about the biological activity of Yki (Goulev et al., 2008; Wu et 
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al., 2008; Zhang et al., 2008b). It has been reported in mammalian cells, that as much as 
75% of TEAD2 interacts with YAP (Vassilev et al., 2001). Moreover, a yeast two-hybrid 
screen of a human transcription factor pool also identified TEADs as the targets that are 
most potently activated by YAP (Zhao et al., 2008). The interaction between TEAD and 
YAP was initially found to require TEAD C-terminal domain for YAP binding and the 
N-terminal of YAP as the corresponding TEAD binding domain (Vassilev et al., 2001). 
Only recent studies have solved the three-dimensional structure of mouse and human 
TEAD-YAP complex, providing important insights into the molecular basis of this 
interaction. The C-terminal domain of TEAD forms a globular structure with a β-
sandwich fold surrounded by  four α-helices on one side, while the N-terminal domain of 
YAP wraps around TEAD, forming extensive interactions (Chen et al., 2010; Li et al., 
2010). Deletion of TEADs or mutation of TEAD Y406/YAP S94 (leading to disruption of 
TEAD-YAP/TAZ interaction) hinders the nuclear localization of YAP/TAZ and fades 
the regulation of the majority of YAP/TAZ-dependent genes, contributing to a highly 
diminished activity of YAP/TAZ in promoting cell proliferation, oncogenic 
transformation, and EMT (Lei et al., 2008; Zhao et al., 2008; Zhao et al., 2009; Chan et 
al., 2009; Zhang et al., 2009). Additionally, deletion of both TEAD1 and 2 demonstrated 
the same results obtained with YAP deletion, that of decreased cell proliferation and 
increased apoptosis (Sawada et al., 2008).
Various gene promoters were identified to be targeted by YAP/TAZ, mediating their 
transcriptional activity. Cyclin E, like in Drosophila, was found to be induced by  YAP in 
vitro (Zender et al., 2006), although in vivo studies did not report a significant 
upregulation (Dong et al., 2007). Similarly to what was observed in Drosophila, 
induction of Birc2/cIAP1 and to a higher extent Birc5/survivin (Diap1 homologs) by 
YAP was reported in mammals. These genes were shown to encode negative regulatory 
proteins that prevent apoptotic cell death (Dong et al., 2007; Hao et al., 2008). Bantam, 
which encodes a miRNA in Drosophila, is not conserved in the mammalian genome, 
and a functional counterpart has not been identified yet. However, other proteins 
including many cytokines such as CTGF and the plasma protein AFP are upregulated by 
YAP/TAZ in mammals (Zhao et al., 2007; Dong et al., 2007; Zhao et al., 2008; Zhou et 
al., 2009). In fact, CTGF was demonstrated to be a direct target gene induced by 
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TEAD-YAP/TAZ complex, mediating cell proliferation, adhesion, and migration (Zhao 
et al., 2008; Zhang et al., 2009). Moreover, AFP was identified as a candidate gene of 
YAP associated with hepatocyte proliferation (Dong et al., 2007).
Drosophila Mammalian Homolog/s Encoding Protein
Role in Hippo 
Signaling Pathway
Hpo Mst1/2 Ste-20 family protein kinase
Bind Sav/WW45 and 
Mats/Mob1 and 
phosphorylate Mats/
Mob1 and Wts/
Lats1/2
Sav WW45 WW domain adaptor protein
Binds Hpo/Mst1/2, 
the complex binds 
and phosphorylates 
Wts/Lats1/2 
Wts Lats1/2 NDR family protein kinase
Binds Mats/Mob1 
and phosphorylates 
Yki/YAP/TAZ
Mats Mob1 Mob1-related protein
Binds Hpo/Mst1/2 
and Wts/Lats1/2, 
complex enhances 
activity of Wts/
Lats1/2
Yki YAP/TAZ Transcriptional coactivator
Phosphorylated form 
binds 14-3-3 protein, 
leads to cytoplasmic 
retention and its 
inactivation.
Unphosphorylated 
form binds Sd/
TEAD, leads to its 
activation and 
translocates to the 
nucleus. 
Sd TEAD Transcription factor
Binds Yki/YAP/TAZ 
to regulate its target 
gene transcription
Table 2  Genes involved in the Drosophila and mammalian Hippo signaling pathway.
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Chapter 2
Aim of Study
The CAR ligand TCPOBOP was previously reported to induce hepatocyte proliferation 
after a single dose resulting in efficient hepatomegaly  in mice. However, no evidence 
has been provided about its effect on liver proliferation response following repeated 
administration. Thus the first aim of this study was:
- to establish whether hepatocytes proliferate every time they are exposed to the 
mitogen TCPOBOP or if a size-control mechanism exists that prevents further 
growth of the liver mass in mice. 
Recent studies identified the Hippo pathway as a regulator of organ size (comprising the 
liver) mediating its function through the control of cell proliferation and apoptosis in 
genetically modified mouse models. So the objective of this research was furthered:
- to investigate whether the Hippo pathway is eventually involved in the control of 
liver size following further challenge with this mitogen in mice.
Moreover, it was formerly shown that TCPOBOP other than being able to induce 
hepatomegaly after a single dose, can also act as a non-genotoxic liver carcinogen 
following chronic administration in mice. Hence another aim of this study was:
- to analyze the tumor incidence at various time points in a mouse carcinogenesis 
model, whereby tumors are initiated with a single dose of DENA and promoted 
by chronic exposure to the CAR agonist, TCPOBOP.
Lately, it was demonstrated that the Hippo pathway is not only implicated in the 
regulation of organ size but also that its dysregulation leads to carcinogenesis (including 
HCC) in transgenic mouse models. Therefore the final objective of this research was:
- to determine the subsequent role of the Hippo pathway in the DENA + 
TCPOBOP-induced HCC in mice.
Current reports have suggested that the Hippo pathway networks with other well-
established pathways, including the Wnt pathway in genetically  modified mouse 
models. If an involvement of the Hippo pathway in the DENA + TCPOBOP-induced 
HCC will be observed, to further elucidate this correlation between the Hippo and Wnt 
pathway, we will analyze such pathway cooperation in these liver cancer cells.
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Chapter 3
Materials and Methods
3.1 - Animals
Eight-week old female C3H/HeNCrl mice were purchased from Charles River (Milan, 
Italy). On arrival, the animals were given a rodent standard diet (Standard Diet 4RF21, 
Mucedola, Milan, Italy) and water ad libitum with alternating 12 hour dark/light cycles 
and acclimatized to laboratory conditions for 1 week before the start of the experiment. 
Temperature and humidity were controlled for the entire period of experimentation. 
Animals were maintained in accordance with the Universities Federation for Animal 
Welfare Handbook on the Care and Management of Laboratory Animals, and the 
Guidelines of the Animal Ethics Committee of the University of Cagliari. After 
acclimatization, the mice were randomized into four experimental protocols. Five to 
eight mice per experimental group were used.
3.2 - Experimental protocols
Fig. 4  Schematic representation of Experimental Protocol I
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In Experimental Protocol I, two groups of mice were given 3 mg/kg body weight  of 
the mitogen TCPOBOP (Cat. No. T1443, Sigma-Aldrich, St. Louis, MO, USA) 
dissolved in dimethyl sulfoxide (DMSO)-corn oil solution (Cat. No. D8418, Sigma-
Aldrich, St. Louis, MO, USA), intragastrically. A group was sacrificed after 1 week. The 
remaining group was treated with another dose of TCPOBOP a week after the first dose 
and sacrificed 1 week after the last dose. The control group received an equivalent 
volume of the solvent. For determination of hepatocyte proliferation, all groups received 
5-bromo-2’-deoxyuridine (BrdU) (Cat. No. B5002, Sigma-Aldrich, St. Louis, MO, 
USA) in drinking water [1 mg/ml] for 1 week before being sacrificed.
Fig. 5  Schematic representation of Experimental Protocol II
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In Experimental Protocol II, two groups of mice were given intragastrically 3 mg/kg 
body weight of TCPOBOP. A group was sacrificed 1 month later. The remaining group 
was administered a further dose of TCPOBOP a month after the initial dose and 
sacrificed 1 week after the ultimate dose. The control group received an equivalent 
volume of the solvent. All mice received BrdU in drinking water for 1 week before 
being sacrificed.
Fig. 6  Schematic representation of Experimental Protocol III
In Experimental Protocol III, five groups of mice were administered 3 mg/kg body 
weight of TCPOBOP, intragastrically. Subsequently, three groups were sacrificed 24, 36 
hours and 7 days later. The other groups were given another dose of TCPOBOP, a week 
after the initial dose, and sacrificed 24 and 36 hours after the final dose. The respective 
controls received an equivalent volume of the solvent. Mice received BrdU in drinking 
water for 24 or 36 hours, depending on the experimental group, before being sacrificed.
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Fig. 7  Schematic representation of Experimental Protocol IV
In Experimental Protocol IV, mice were divided into three groups. The first  group was 
given a single intraperitoneal injection of DENA (Cat. No. N0756, Sigma-Aldrich, St. 
Louis, MO, USA), dissolved in saline, at a dose of 90 mg/kg body weight  followed by 
weekly  doses of TCPOBOP (3 mg/kg body  weight) given intragastrically. The second 
group received a single intraperitoneal injection of DENA (90 mg/kg body weight) 
followed by weekly intragastric administrations of corn oil. The last group was only 
given weekly  intragastric doses of TCPOBOP (3 mg/kg body weight). Mice from the 
three respective groups were sacrificed at three time periods: after 10, 20 and 28 weeks. 
All mice received BrdU in drinking water for 3 days before being sacrificed.
In all protocols, immediately after mice were sacrificed, liver sections were fixed in 
10% buffer formalin and processed for staining with hematoxylin-eosin (H&E) for 
routine morphology  or immunohistochemistry. The remaining liver was snap-frozen in 
liquid nitrogen and kept at -80℃ until use.
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3.3 - Immunohistochemistry
3.3.1 - BrdU staining
Four-micrometer-thick sections were deparaffinized, treated with 2 N HCl for 1 hour, 
then immersed in 0.1% Trypsin Type II-S from Porcine Pancreas (Cat. No. T7409, 
Sigma-Aldrich, St. Louis, MO, USA) for 30 minutes at  37℃, and incubated 
sequentially with 1:10 Goat Serum (Normal) (Cat. No. X0907, Dako Denmark A/S, 
Glostrup, Denmark) for 30 minutes, 1:50 Mouse Monoclonal Anti-BrdU Antibody (Cat. 
No. 347580, Becton Dickinson, San Jose, CA, USA) for 1 hour and 30 minutes, and 
with Dako EnVision+® System Labelled Polymer-HRP Anti-Mouse (Cat. No. K4001, 
DakoCytomation, Carpinteria, CA, USA) for 30 minutes. The sites of peroxidase 
binding were detected by  3,3’-diaminobenzidine tetrahydrochloride hydrate (DAB) 
(Cat. No. 261890, Sigma-Aldrich, St. Louis, MO, USA). Counter staining was 
performed with Harris Hematoxylin Solution (Cat. No. HHS32, Sigma-Aldrich, St. 
Louis, MO, USA). A segment of the duodenum, an organ with a high rate of cell 
proliferation, was included from each mouse to confirm delivery of the DNA precursor.
Labelling index was expressed as number of BrdU-positive hepatocyte nuclei per 100 
nuclei. At least 2500 hepatocyte nuclei for each liver were scored.
3.3.2 - YAP staining
Four-micrometer-thick sections were deparaffinized, immersed in EnVision™ FLEX 
Target Retrieval Solution, High pH (50X) (Cat. No. DM828, Dako Denmark A/S, 
Glostrup, Denmark) that had been preheated to 95℃ in a water bath and then heat-
treated at  95℃ for 40 minutes, and incubated sequentially with EnVisionTM FLEX 
Peroxidase-Blocking Reagent (Cat. No. SM801, Dako Denmark A/S, Glostrup, 
Denmark) for 5 minutes, 1:100 Rabbit Polyclonal Anti-YAP (H-125) Antibody  (Cat. No. 
sc-15407, Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 hour and with 
EnVisionTM FLEX/HRP Detection Reagent (Cat. No. SM802, Dako Denmark A/S, 
Glostrup, Denmark) for 30 minutes. The sites of peroxidase binding were detected by 
the mixture of EnVisionTM FLEX DAB+ Chromogen (Cat. No. DM827, Dako Denmark 
A/S, Glostrup, Denmark), a concentrated DAB solution, and EnVisionTM FLEX 
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Substrate Buffer (Cat. No. SM803, Dako Denmark A/S, Glostrup, Denmark) containing 
hydrogen peroxide. Counter staining was performed with Harris Hematoxylin Solution.
3.3.3 - Glutamine synthetase (GS) staining 
Five-micrometer-thick sections were deparaffinized and incubated sequentially  with 
1:30 Goat Serum (Normal) for 5 minutes, 1:1000 Rabbit Polyclonal Anti-GS Antibody 
overnight at 4℃ (Cat. No. G2781, Sigma-Aldrich, St. Louis, MO, USA), again with 
1:30 Goat Serum (Normal) for 5 minutes, and with Dako EnVision+® System Labelled 
Polymer-HRP Anti-Rabbit (Cat. No. K4003, DakoCytomation, Carpinteria, CA, USA) 
for 30 minutes. The sites of peroxidase binding were detected by DAB. Counter staining 
was performed with Mayer’s Hematoxylin Solution (Cat. No. 05-M06002, Bio-Optica, 
Milan, Italy).
3.3.4 - Cyp2e1 staining 
Ten-micrometer-thick cryostat sections were fixed and incubated sequentially with 1:30 
Goat Serum (Normal) for 5 minutes, 1:1000 Rabbit Polyclonal Anti-Cyp2e1 Antibody 
overnight at 4℃ (Cat. No. MFO-100, Stressgen Biotechnologies Corporation, Victoria, 
BC, Canada), again with 1:30 Goat Serum (Normal) for 5 minutes, and with 1:20 Dako 
EnVision+® System Labelled Polymer-HRP Anti-Rabbit for 60 minutes. The sites of 
peroxidase binding were detected by DAB. Counter staining was performed with 
Mayer’s Hematoxylin Solution.
3.4 - Western blot
Total cell extracts were prepared from frozen livers powdered in liquid nitrogen-cold 
mortar. Equal amounts of powder (≈50 mg) from different animals were resuspended in 
1 ml Triton lysis buffer containing several protease inhibitors (1% Triton X-100, 50 mM 
Tris-HCl pH 7.4, 140 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol 
(DTT), 1 mM  phenylmethanesulfonyl fluoride (PMSF), 10 mM  sodium fluoride (NaF), 
5 mM  iodoacetic acid (IAA), and 10 µg/ml of aprotinin, leupeptin, and pepstatin each). 
All inhibitors used were purchased from Boehringer Mannheim GmbH (Mannheim, 
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Germany) with the following exceptions: DTT, PMSF, and NaF, which were purchased 
from Sigma-Aldrich (St. Louis, MO, USA), and IAA, which was bought from ICN 
Biomedicals (Irvine, CA, USA). Extracts were incubated for 30 minutes on ice, 
centrifuged at 12000 rpm at 4°C, and the supernatants recovered. Nuclear extracts for 
YAP were prepared according to Timchenko et al. (1996). The protein concentration of 
the resulting total and nuclear extracts was determined according to the Bradford 
method (Bradford, 1976) using bovine serum albumin  (BSA) (Cat. No. A9647, Sigma-
Aldrich, St. Louis, MO, USA) as standard. For immunoblot analysis, equal amounts 
(from 100 to 150 µg/lane) of proteins were electrophoresed on 8 to 12% sodium 
dodecyl sulfate polyacrylamide (SDS-PAGE) homogenous gels (Cat. No. L4522, 
Sigma-Aldrich, St. Louis, MO, USA and Cat. No. 161-0156, Bio-Rad Laboratories, 
Hercules, CA, USA). After gel electrotransfer onto nitrocellulose membranes (Cat. No. 
162-0097, Bio-Rad Laboratories, Hercules, CA, USA) at 300 mA overnight or 800 mA 
for 2 to 4 hours, to ensure equivalent protein loading and transfer in all lanes, the 
membranes and gels were stained with 0.5% (w/v) Ponceau S dye (Cat. No. 02190644, 
ICN Biomedicals, Irvine, CA, USA) in 1% acetic acid for 5 minutes, and with 
Coomassie Brilliant Blue (Cat. No. 04808274, ICN Biomedicals, Irvine, CA, USA) in 
10% acetic acid for 30 minutes, respectively. After blocking with 5% non-fat dry milk 
or 5% BSA in Tris-buffered saline containing 0.05% Tween 20 (TBST) (Cat. No. 
P7949, Sigma-Aldrich, St. Louis, MO, USA) at room temperature for 1 hour or 
overnight at  4°C, membranes were washed in TBST and then incubated with the 
appropriate primary antibodies diluted in blocking buffer. Whenever possible, the same 
membrane was used for detection of the expression of different proteins. Depending on 
the origin of primary antibody, filters were incubated at room temperature with either 
anti-mouse or anti-rabbit  horseradish peroxidise-conjugated IgG (Cat. No. sc-2806 and 
sc-2808, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunoreactive bands 
were identified with SuperSignal® West Pico Chemiluminescent Substrate, as described 
by the manufacturer (Cat. No. 34080, Pierce, Rockford, IL, USA). The relative 
proportions of each sample were then estimated by densitometric analysis of the 
intensity of each band by using the image analysis software ImageJ (NIH, Bethesda, 
MD, USA).
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Primary  antibodies used for immunoblotting were the following: mouse monoclonal 
antibodies directed against actin (AC40) (Cat. No. A4700, Sigma-Aldrich, St. Louis, 
MO, USA), cyclin D1 (72-13G), proliferating cell nuclear antigen (PCNA) (PC10) (Cat. 
No. sc-450 and sc-56, Santa Cruz Biotechnology, Santa Cruz, CA, USA), and β-catenin 
(Clone 14) (Cat. No. 610154, BD Transduction Laboratories, San Diego, CA, USA); 
and rabbit polyclonal antibodies against cyclin A (C-19) (Cat. No. sc-596, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), and YAP (Cat. No. 4912, Cell Signaling 
Technology, Beverly, MA, USA).
3.5 - DNA sequencing 
Total DNA was purified from frozen liver samples using QIAamp® DNA Mini Kit  (Cat. 
No. 51304, Qiagen GmbH, Hilden, Germany). The quantity of the DNA samples was 
measured using a NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific, 
Wilmington, DE, USA) and the quality  was assessed by calculating the ratio of 
absorbance at 260 nm to absorbance at 280 nm (A260/A280 ratio). Polymerase chain 
reaction (PCR) was conducted in a 50 µl reaction volume containing 500 ng of DNA, 
10X Taq Buffer with KCl, 10 mM  dNTP mixture, 10 µM of each primer, and 1 U of Taq 
DNA Polymerase (Cat. No. EP0404, Fermentas GmbH, St. Leon-Rot, Germany). 
GeneAmp® PCR System 9700 thermal cycler (Applied Biosystems, Foster City, CA, 
USA) was programmed with an initial denaturation time of 5 minutes at 95℃, followed 
by 35 cycles with denaturation at 95℃ for 1 minute, annealing 64℃/58℃/65℃ (for 
beta-catenin 1 gene (Ctnnb1) primers (yielding a 1473 base pair (bp) fragment)/Ctnnb1 
primers (yielding a 248 bp  fragment)/harvey rat sarcoma virus oncogene 1 gene (Hras1) 
primers (yielding a 166 bp fragment) respectively) for 1 minute, and elongation at  72℃ 
for 1 minute. A final extension of 10 minutes at  72℃ was performed. For amplification 
the following gene-specific primer sequences were used: Ctnnb1 (yielding a 1473 bp 
f r a g m e n t ) - 5 ’ - A G C T C A G C G C A G A G C T G C T G - 3 ’ ( s e n s e ) a n d 5 ’ -
CCTTCCTGATGGAGCAGGAGA-3’ (antisense); Ctnnb1 (yielding a 248 bp fragment) 
- 5 ’ - A C T C T G T T T T T A C A G C T G A C C - 3 ’ ( s e n s e ) a n d 5 ’ -
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TTTACCAGCTACTTGCTCTTG-3’ (antisense); Hras1 (yielding a 166 bp fragment) - 
5 ’ - G A G A C A T G T C T A C T G G A C A T C T T - 3 ’ ( s e n s e ) a n d 5 ’ -
GCTAGCCATAGGTGGCTCACCTG-3’ (antisense). Amplification products were 
loaded on a 2% agarose gel (Cat. No. A5093, Sigma-Aldrich, St. Louis, MO, USA) or a 
10% polyacrylamide gel (Cat. No. 3029, Carl Roth GmbH, Karlsruhe, Germany), 
depending on the length of the resulting fragments. DNA bands were then stained with 
bromophenol blue (Cat. No. B0126, Sigma-Aldrich, St. Louis, MO, USA) and 
visualized with ethidium bromide solution (Cat. No. 46067, Sigma-Aldrich, St. Louis, 
MO, USA) on a MacroVue UVis-20 transilluminator (Hoefer, San Francisco, CA, USA) 
to make sure that the desired amplification product was obtained. PCR products were 
sequenced in both directions using the same primers employed for amplification on a 
3730xl DNA Analyzer (96-capillary  array) (Applied Biosystems, Foster City, CA, USA) 
by BMR Genomics (Padua, Italy). Nucleotide sequences were analyzed using the 
software ChromasPro Version 1.5 (Technelysium Pty Ltd, Tewantin, QLD, Australia).
3.6 - Restriction fragment length polymorphism (RFLP)
The previous amplification product (166 bp  fragment) obtained by the Hras1 primers 
was used with the following specific restriction endonucleases.
The specific restriction enzyme digest for the single base substitution sequence ‘CAT’ 
was conducted in a 20 µl reaction volume containing 800 ng of DNA, 1X NEBuffer 4 
(Cat. No. B7004, New England BioLabs GmbH, Frankfurt, Germany) and 10 U of 
BspHI enzyme (Cat. No. R0517, New England BioLabs GmbH, Frankfurt, Germany) at 
a temperature of 37℃ for 60 minutes. Moreover, digestion for the point mutated 
sequence ‘CGA’ was carried out in a 20 µl reaction volume consisting of 800 ng of 
DNA and 10 U of TaqI enzyme (Cat. No. ER0671, Fermentas GmbH, St. Leon-Rot, 
Germany) at a temperature of 65℃ for 60 minutes. Likewise, that for the ‘CTA’ mutated 
sequence was done in a 20 µl reaction volume including 800 ng of DNA and 20 U of 
XbaI enzyme (Cat. No. R0145, New England BioLabs GmbH, Frankfurt, Germany) at a 
temperature of 37℃ for 60 minutes. In addition, enzyme digest for the single base 
Chapter 3                                                                                                                     Materials and Methods
31
substitution sequence ‘AAA’ was conducted in a 20 µl reaction volume composed of 
800 ng of DNA, 1X NEBuffer 4, 1X BSA and 5 U of Hpy188III enzyme (Cat. No. R 
0622, New England BioLabs GmbH, Frankfurt, Germany) at a temperature of 37℃ for 
20 hours. Digestion products were loaded on a 10% polyacrylamide gel, stained with 
bromophenol blue and visualized with ethidium bromide solution on a MacroVue 
UVis-20 transilluminator. Analysis of the presence of DNA fragments of different 
lengths was done with the help of GeneRuler™ 100 bp Plus DNA Ladder (Cat. No. 
SM0321, Fermentas GmbH, St. Leon-Rot, Germany). The presence of the following 
fragments lengths in the various enzyme digestion reactions indicated single base 
substitutions:
Restriction Digestion DNA Fragment/s
Enzyme Site Wild Type
CAA
Point Mutation
CAT/CGA/CTA/AAA
BspHI 5’...T|CATGA...3’3’...AGTAC|T...5’ 166 bp 130 bp + 36 bp
Taq I 5’...T|CGA...3’3’.. .AGC|T...5’ 125 bp + 41 bp 89 bp + 41 bp + 36 bp
XbaI 5’...T|CTAGA...3’3’...AGATC|T...5’ 166 bp 130 bp + 36 bp
Hpy188III 5’...TC|NNGA...3’3’...AGNN|CT...5’ 129 bp + 35 bp 166 bp
A positive control was included in each specific restriction enzyme digest  to make sure 
that the specific restriction endonucleases completed their digestion.
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3.7 - Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
3.7.1 - Analysis of miRNA
Total RNA was extracted from frozen liver samples using Trizol® Reagent (Cat. No. 
15596, Invitrogen, Carlsbad, CA, USA). The quantity  of the RNA samples was 
measured using a NanoDrop ND-1000 Spectrophotometer and the quality was assessed 
by migration of RNA on agarose gel. Complementary DNA (cDNA) was synthesized 
using the TaqMan® MicroRNA Reverse Transcription Kit (Cat. No. 4366596, Applied 
Biosystems, Foster City, CA, USA) in accordance with the manufacturer’s instructions. 
qRT-PCR amplification was performed with the reverse transcription product, TaqMan® 
2X Universal PCR Master Mix, No AmpErase® UNG (Cat. No. 4324018, Applied 
Biosystems, Foster City, CA, USA), miRNA-375 primers and probe mix (Cat. No. 
4373027, Applied Biosystems, Foster City, CA, USA), which was incubated in a 96-
well plate at 95℃ for 10 minutes, followed by  40 cycles of 95℃ for 15 seconds each 
and 60℃ for 1 minute, respectively on a 7300 Real-Time PCR System (Applied 
Biosystems, Foster City, CA, USA). The endogenous control snoRNA202 (Cat. No. 
4380914, Applied Biosystems, Foster City, CA, USA) was used to normalize miRNA 
expression levels.
3.7.2 - Analysis of messenger RNA (mRNA)
2 µg of total RNA, extracted with RNeasy® Plus Mini Kit (Cat. No. 74134, Qiagen 
GmbH, Hilden, Germany), was reverse transcribed using the High-Capacity  cDNA 
Reverse Transcription Kit (Cat. No. 4374966, Applied Biosystems, Foster City, CA, 
USA) according to the manufacturer’s protocol. cDNA together with TaqMan® Gene 
Expression Master Mix (Cat. No. 4369016, Applied Biosystems, Foster City, CA, 
USA), CAR primers and probe mix (Cat. No. Mm00437986_m1, Applied Biosystems, 
Foster City, CA, USA), Cyp2b10 primers and probe mix (Cat. No. Mm00456591_m1, 
Applied Biosystems, Foster City, CA, USA), Birc5 primers and probe mix (Cat. No. 
Mm00599749_m1, Applied Biosystems, Foster City, CA, USA), or AFP primers and 
probe mix (Cat. No. Mm00431715_m1, Applied Biosystems, Foster City, CA, USA) 
was used to carry out qRT-PCR amplification. The thermal cycling conditions were 
50℃ for 2 minutes, 95℃ for 10 minutes, followed by 40 cycles of 95℃ for 15 seconds 
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each and 60℃ for 1 minute, respectively. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (Cat. No. 4352932E, Applied Biosystems, Foster City, CA, USA) was used 
as the endogenous normalizer.
In both procedures, the relative amount of miRNA/mRNA was determined with the 
2-ΔΔCT method, where ΔΔCT = (CT target - CT endogenous)sample - (CT target - CT endogenous)calibrator. 
3.8 - Semiquantitative reverse transcription polymerase chain reaction (sqRT-PCR)
sqRT-PCR was conducted in a 50 µl reaction volume containing 50 ng of cDNA, 10X 
High Fidelity PCR Buffer, 50 mM MgSO4, 10 mM dNTP mixture, 5 µM  of each primer, 
and 1 U of Platinum® Taq DNA Polymerase High Fidelity (Cat. No. 11304, Invitrogen, 
Carlsbad, CA, USA). GeneAmp® PCR System 9700 thermal cycler was programmed 
with an initial denaturation time of 5 minutes at  94℃, followed by an appropriate 
number of cycles with denaturation at 94℃ for 30 seconds, annealing at 58℃ for 30 
seconds, and elongation at 72℃ for 1 minute. A final extension of 5 seconds at  72℃ 
was performed. Thirty-two and twenty cycles were found to be optimal for CTGF and 
18S, respectively. For amplification the following gene-specific primer sequences were 
used: CTGF - 5’-GCGCCAAGCAGCTGGGAGAA-3’ (sense) and 5’-
G C A G C T A G G G C A G G G C C A A C - 3 ’ ( a n t i s e n s e ) ; 1 8 S - 5 ’ -
A A A C G G C T A C C A C A T C C A A G - 3 ’ ( s e n s e ) a n d 5 ’ -
CCCTCTTAATCATGGCCTCA-3’ (antisense). The PCR products were loaded on 2% 
agarose gel, stained with bromophenol blue and visualized with ethidium bromide 
solution on a MacroVue UVis-20 transilluminator. The relative proportions of each 
sample were then estimated by densitometric analysis of the intensity  of each band by 
using the image analysis software ImageJ.
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3.9 - Statistical analysis
Instant statistics software (GraphPad InStat Software Inc., San Diego, CA, USA) was 
used to analyze the data. The results of multiple observations were presented as the 
mean ±  standard error (SE) of at least  two separate experiments. A P value of <0.05 was 
regarded as a significant difference between groups.
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Chapter 4
Results and Discussion
4.1 - Effect of repeated doses of TCPOBOP on hepatocyte proliferation in a normal liver
TCPOBOP is a well known powerful inducer of hepatocyte proliferation in mice 
(Dragani et al., 1985; Manenti et al., 1987), when administered in a single dose, 
nevertheless no evidence has been provided about its effect on the liver size following 
repeated administration. For this purpose, Experimental Protocol I was designed.
Statistical analyses showed that a single injection of TCPOBOP was able to induce 
doubling of the liver mass in a week (10.96 ± 0.27% vs. 5.31 ± 0.08% of control 
animals), but the same cannot be said after the second dose, where the difference in 
liver mass, when compared to the first dose group, was almost negligible (11.39 ± 
0.19% vs. 10.96 ± 0.27%) (Fig. 8). The increase in liver mass observed after the first 
dose of the mitogen was largely  due to hepatocyte proliferation, as shown by a striking 
increase in percentage of BrdU-positive nuclei in mice receiving the first dose of 
TCPOBOP when compared to their respective controls (43.95 ± 1.88% vs. 3.83 ± 
0.57%). On the contrary, there was no significant hepatocyte proliferation in mice 
treated with a second dose of the mitogen when compared to control animals (5.91 ± 
0.86% vs. 3.83 ± 0.57%) (Fig. 9, 10).
         
Fig. 8  Percentage of liver to body weight in mice belonging to the various groups described 
in Experimental Protocol I. Results are expressed as means ± SE of five mice per group. 
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Fig. 9  Percentage of BrdU-positive nuclei in liver sections of mice belonging to the various 
groups described in Experimental Protocol I. Results are expressed as means ± SE of five 
mice per group.
Fig. 10  Representative microscopic view of liver sections from mice belonging to the 
various groups described in Experimental Protocol I stained immunohistochemically for 
BrdU (original magnification x 20).
Such analyses made it clear that hepatocytes receiving a second dose of TCPOBOP a 
week after the first dose were not able to proliferate at the same rate as those receiving a 
single dose of the mitogen. 
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4.1.1 - Xenobiotic metabolism following repeated administration of the mitogen
TCPOBOP is an agonist ligand for the nuclear receptor CAR. The protein binds to DNA 
as a monomer or a heterodimer with the RXR and induces the transcription of target 
genes implicated in drug metabolism, such as CYP family members, especially 
Cyp2b10 (Poland et al., 1980; Tzameli et al., 2000). In order to clarify if the absence of 
a significant hepatocyte proliferation response following repeated treatments with 
TCPOBOP was related to a xenobiotic metabolism issue, qRT-PCR analysis of CAR 
and Cyp2b10 mRNAs was performed. 
Statistical interpretation showed that the relative quantity (RQ) of CAR mRNA in the 
livers of mice injected with the first dose of TCPOBOP, when compared to the 
respective controls, was considerably decreased (0.27 ± 0.01 vs. 1.01 ± 0.10). Similarly, 
when livers treated with a second dose of the mitogen were compared to the control 
group, the relative amount of CAR mRNA was equally repressed (0.30 ± 0.03 vs. 1.01 ± 
0.10). Since variation in the downregulation of this nuclear receptor in livers treated 
with one or two doses of the mitogen was insignificant, it was assumed that the agonist 
effect of TCPOBOP was identical in both groups (Fig. 11). Moreover, evaluation of 
Cyp2b10 mRNA relative quantities demonstrated that there was a notable upregulation 
after administration of the mitogen (27.33 ± 3.08 after the first dose of TCPOBOP / 
29.02 ± 2.98 after the second dose of TCPOBOP vs. 1.00 ± 0.09 of controls). The 
difference in the increased expression of this target  gene was negligible in livers 
administered with one or two doses of the mitogen, indicating that Cyp2b10 induction 
was equal in both treated groups. This confirms that TCPOBOP was metabolized at the 
same extent after the respective doses, hence the mitogenic effect  should be alike (Fig. 
12).
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Fig. 11  RQ of CAR mRNA levels in livers of mice belonging to the various groups 
described in Experimental Protocol I, determined by qRT-PCR analysis. GAPDH was used 
as an endogenous normalizer. Results are expressed as means ± SE of three livers per group.
Fig. 12  RQ of Cyp2b10 mRNA levels in livers of mice belonging to the various groups 
described in Experimental Protocol I, determined by qRT-PCR analysis. GAPDH was used 
as an endogenous normalizer. Results are expressed as means ± SE of three livers per group.
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4.1.2 - Time interval issue for hepatocytes to reply to a further mitogenic stimulus
In order to elucidate if the refractory effect on hepatocyte proliferation, observed after 
the second dose of TCPOBOP, was related to a short time interval between the two 
doses, thus rendering hepatocytes unable to further respond to the mitogen, another 
similar protocol, consisting of the same previous experimental groups, was set up with 
the exception that the time period between the first and second dose of TCPOBOP was 
of 4 weeks instead of 1 week (Experimental Protocol II). 
Statistical evaluation of the percentage liver to body weight confirmed approximately 
the same results obtained with the previous experimental protocol. Particularly, the first 
dose of TCPOBOP was able to increase the liver weight by a twofold (10.02 ± 0.26% 
vs. 5.02 ± 0.09% of control animals), while the second dosage resulted in a slightly 
bigger liver, when compared to the first dose group, although not statistically significant 
(10.63 ± 0.14% vs. 10.02 ± 0.26%) (Fig. 13). 
              
Fig. 13  Percentage of liver to body  weight in mice belonging to the various groups 
described in Experimental Protocol II. Results are expressed as means ± SE of five mice per 
group. 
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Similarly  to what was observed in Experimental Protocol I, immunohistochemical 
analyses of the percentage BrdU-positive nuclei showed that the first administration of 
TCPOBOP resulted in a staggering surge of BrdU-incorporation when compared to the 
control group (40.19 ± 2.44% vs. 4.18 ± 0.42%), while the rate of proliferation was still 
much lower with two doses of the mitogen, although there was a considerable increase 
in hepatocyte proliferation compared to control animals (13.16 ± 1.17% vs. 4.18 ± 
0.42%) (Fig. 14). 
              
Fig. 14  Percentage of BrdU-positive nuclei in liver sections of mice belonging to the 
various groups described in Experimental Protocol II. Results are expressed as means ± SE 
of five mice per group.
This study demonstrates that a longer time period between the two doses did not 
actually change the proliferation response of the hepatocytes following repeated 
treatments with the same mitogen.
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4.2 - Role of the Hippo pathway in liver refractoriness to repeated administration of  
TCPOBOP
Recent studies on organ size control reported, in both Drosophila and mammals, the 
critical role of Hippo kinase cascade, a growth-suppressive pathway that ultimately 
antagonises the transcriptional coactivator YAP (Camargo et al., 2007; Dong et al., 
2007). Hence, to investigated whether Hippo pathway activation might be the 
homeostatic mechanism responsible for the liver refractoriness to further challenge of 
the mitogen Experimental Protocol III was carried out.
Statistical analyses of this kinetic study supported the previous results, in that, the liver 
mass peaks a week after the first administration of TCPOBOP (11.64 ± 0.23% vs. 5.77 ± 
0.14% of control animals), but further growth ceases following a second dose of the 
mitogen (11.30 ± 0.09% / 11.85 ± 0.11% 24 and 36 hours after the second dose of 
TCPOBOP vs. 11.64 ± 0.23% of control animals) (Fig. 15). It was also confirmed that 
hepatocyte proliferation was responsible for the significant increase in liver mass 
noticed after the first  dose of the mitogen with percentage of BrdU-positive nuclei 
peaking after 36 hours (30.88 ± 0.96% vs. 2.86 ± 1.11% of controls). Moreover, 
according to previous data, it was shown that after the second administration of 
TCPOBOP, hepatocyte proliferation was negligible, when compared to control animals 
(2.25 ± 0.62% / 4.05 ± 0.09% 24 and 36 hours after the second dose of the mitogen vs. 
2.86 ± 1.11% of controls) (Fig. 16).
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Fig. 15  Percentage of liver to body  weight in mice belonging to the various groups 
described in Experimental Protocol III. Results are expressed as means ± SE of five mice per 
group. 
Fig. 16  Percentage of BrdU-positive nuclei in liver sections of mice belonging to the 
various groups described in Experimental Protocol III. Results are expressed as means ± SE 
of five mice per group.
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The increased hepatocyte entry into the S phase, observed by  BrdU staining in liver 
sections of mice receiving a single dose of TCPOBOP, was associated with enhanced 
levels of the cell cycle-related proteins, cyclin D1, cyclin A and PCNA, all indicators of 
proliferation when overexpressed (Pines, 1995). Oppositely, after the second dose of 
TCPOBOP, no such increase was noticed, in conformity with the previously observed 
inhibitory effect response on hepatocyte proliferation exerted by  the second dose of the 
same mitogen (Fig. 17).
Accordingly to its growth promoting effect, Western Blot analysis indicated 
substantially  higher levels of YAP after a single dose of TCPOBOP. On the contrary, no 
increase of YAP levels was noticed after the second dose of the mitogen (Fig. 17), 
presumably as a consequence of the activation of the Hippo growth-suppressive 
pathway, leading to YAP phosphorylation, thus, inactivation of the protein.
Fig. 17  Levels of cyclin D1, cyclin A, PCNA and YAP in total hepatic protein extracts of 
mice belonging to the various groups described in Experimental Protocol III, determined by 
Western Blot analysis. Actin was used as a loading control. Each lane represents a single 
sample.
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As reported in the literature, YAP induces the transcription of many target genes, among 
which of remarkable importance is Birc5/survivin, a member of the inhibitor of 
apoptosis (IAP) gene family, which encode negative regulatory proteins that prevent 
apoptotic cell death (Dong et al., 2007; Hao et al., 2008). qRT-PCR analysis 
demonstrated that the mRNA expression of Birc5 was positively  correlated with the 
expression of YAP protein, since a twenty-fold increase of Birc5 36 hours after the first 
dose of TCPOBOP was observed, whereas only  a two-fold change was noticed after the 
second dose of the mitogen when compared to the control group (Fig. 18). These results 
further support the involvement of YAP, thus of the Hippo signaling pathway, in 
TCPOBOP-induced hepatocyte proliferation. 
Fig. 18  Fold change of Birc5 mRNA levels in livers of mice belonging to the various 
groups described in Experimental Protocol III, determined by qRT-PCR analysis. GAPDH 
was used as an endogenous normalizer. Results are expressed as means ± SE of three livers 
per group.
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4.3 - Analysis of tumor incidence at various time points during DENA + TCPOBOP-
induced carcinogenesis
TCPOBOP, other than being able to induce hepatomegaly  after a single dose, can also 
act as a non-genotoxic liver carcinogen following chronic administration (Dragani et 
al., 1985; Dragani et al., 1987; Diwan et al., 1992). Therefore, Experimental 
Protocol IV was conducted to investigate in TCPOBOP-dependent carcinogenesis if 
DENA-induced mutations allow ‘initiated’ hepatocytes to selectively ‘escape’ from 
such an organ constraint, related to administration of repeated doses of the mitogen, 
thus favoring their clonal expansion and eventually leading to HCC. 
Percentage of liver to body weight at the 10-week time period demonstrated that while 
there was a two-fold increase in TCPOBOP treated livers when compared to those 
exposed to DENA only (11.87 ± 0.13% vs. 5.02 ± 0.10%), no remarkable difference 
between the TCPOBOP and DENA + TCPOBOP group  was observed (11.87 ± 0.13% 
vs. 11.36 ± 0.16%) (Fig. 19). Moreover, the liver to body weight ratio at the 20-week 
time point confirmed the doubling in liver mass of the TCPOBOP group with respect to 
the DENA group (12.31 ± 0.20% vs. 4.76 ± 0.18%), although a three-fold change was 
seen between the DENA + TCPOBOP and DENA group (18.04 ± 1.62% vs. 4.76 ± 
0.18%) (Fig. 20). In addition, percentage of liver to body weight at the 28-week time 
period showed a similar trend to the previous time point, with the difference that there 
was a five-fold increase in the DENA + TCPOBOP group when compared to the DENA 
group (31.57 ± 0.71% vs. 5.87 ± 0.48%) (Fig. 21). This liver weight variation between 
the TCPOBOP and DENA + TCPOBOP group, noticed at the 20 and 28-week time 
points, could be the consequence of the presence of tumors.
Chapter 4                                                                                                                     Results and Discussion
47
Fig. 19  Percentage of liver to body weight in mice belonging to the various 10-week time 
point groups described in Experimental Protocol IV. Results are expressed as means ± SE of 
eight mice per group.
Fig. 20  Percentage of liver to body weight in mice belonging to the various 20-week time 
point groups described in Experimental Protocol IV. Results are expressed as means ± SE of 
eight mice per group.
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Fig. 21  Percentage of liver to body weight in mice belonging to the various 28-week time 
point groups described in Experimental Protocol IV. Results are expressed as means ± SE of 
eight mice per group.
Accordingly, macroscopic analysis showed that while after the 10-week time period 
there was no evidence of hepatic lesions, after the 20-week time point immediate 
macroscopical unifocal nodular lesions were visible in (8/8) livers of the DENA + 
TCPOBOP group solely. Macroscopic lesions were also perceptible in all (8/8) livers of 
the DENA + TCPOBOP group after the 28-week time period, but the multifocal type 
was more frequently found (Fig. 22). 
Fig. 22  Representative macroscopic view of livers from mice belonging to the various 28-
week time point groups described in Experimental Protocol IV. 
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A total of 42 nodular lesions with an average diameter of 6.16 mm were identified in the 
20-week time point livers. The left lateral lobe (assigned according to Cook, 1965) 
presented the highest number of nodules together with the biggest mean diameter of 
such nodules (Table 3, 4). The 28-week time period livers presented slightly less lesions 
(36 nodules) but with a considerably bigger mean diameter (12.89 mm), when 
compared to the 20-week time point livers, indicating the presence of merging nodular 
lesions. 
Left Lobe Median Lobe Right Lobe Caudate Lobe
20-wk time point 24 0 13 5
28-wk time point 14 11 10 1
Table 3  Total number of nodules in the various lobes of livers from mice belonging to the 
DENA + TCPOBOP experimental group.  
Left Lobe Median Lobe Right Lobe Caudate Lobe
20-wk time point 8.63 mm2 - 3.62 mm2 1.00 mm2
28-wk time point 18.21 mm2 4.45 mm2 14.00 mm2 20.00 mm2
Table 4  Average diameter of nodules in the various lobes of livers from mice belonging to 
the DENA + TCPOBOP experimental group.
Microscopic analysis of H&E stained sections demonstrated that 84.62% of the 28-
week time period livers showed trabecular nodules (classified according to 
Vesselinovitch et al., 1978), compared to the 36.84% of the 20-week time point livers, 
indicating that the former lesions were in a more advanced tumor state.
Additional examination of these sections further confirmed that the 28-week time period 
livers exhibited notably  bigger mean tumor area, when compared to the 20-week time 
point ones (4.93 ± 1.07 mm2 vs. 1.70 ± 0.28 mm2). Furthermore, opposite to what was 
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noticed with the macroscopic analysis, more tumors were observed at the 28-week time 
period (6.10 ± 1.08/cm2 vs. 3.16 ± 0.77/cm2 of the 20-week time point livers). This is 
due to the fact that merging nodular lesions under the microscope could still be 
distinguished. These two factors obviously  contributed to a higher tumor mass in livers 
at the 28-week then at the 20-week time period (29.31 ± 4.59% vs. 5.25 ± 1.19%) (Fig. 
23), hence confirming that the difference in liver weight previously observed between 
the DENA + TCPOBOP group  of the 20 and 28-week time point was due to the increase 
in percentage tumor mass. 
Fig. 23  Microscopic tumor analysis of liver sections from mice belonging to the 20 and 28-
week time points of the DENA + TCPOBOP experimental group. Results are expressed as 
means ± SE of eight liver sections per time point.
Microscopic analysis of BrdU stained liver sections belonging to the 20 and 28-week 
time periods revealed very  high proliferation in the tumor zone, while no proliferation 
was seen in the surrounding tissue of the DENA + TCPOBOP group; hence in 
concordance with the inhibitory effect exerted by repeated doses of the mitogen on 
hepatocyte proliferation in normal tissue, observed in the TCPOBOP group  (Fig. 24). 
This explains further that the difference in liver weight between the TCPOBOP and 
DENA + TCPOBOP group, at the 20 and 28-week time points, was due to the 
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proliferating tumors in the latter group, thus confirming the hypothesis that ‘initiated’ 
hepatocytes are able to continue proliferating in spite of such organ constraint.
Fig. 24  Representative microscopic view of liver sections from mice belonging to the 
various 28-week time point groups described in Experimental Protocol IV stained 
immunohistochemically for BrdU (original magnification x 20).
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4.4 - Role of the Hippo pathway in DENA + TCPOBOP-induced HCC
Since the mammalian Hippo circuit is not only implicated in organ size regulation but 
also in tumorigenesis; while its primary effector, YAP, is overexpressed and nuclearly 
localized in multiple types of human cancer (Overholtzer et al., 2006; Steinhardt et al., 
2008), YAP immunohistochemistry was carried out on liver sections belonging to the 
28-week time point of the DENA + TCPOBOP group. As shown in Figure 25, YAP was 
predominantly translocated in the nuclei of tumor cells, while the corresponding tissue 
surrounding the tumor presented primarily cytoplasmic YAP staining. 
Fig. 25  Representative microscopic view of a liver section from a mouse belonging to the 
28-week time point of the DENA + TCPOBOP experimental group stained 
immunohistochemically for YAP (original magnification x 40).
Next, the hypothetic alteration of the Hippo pathway was evaluated in the same hepatic 
tumors by determining YAP total protein extract levels by Western Blot analysis. 
Densitometric analysis showed that in approximately  80% (18/21) of tumor samples, 
levels of YAP increased by  an average fold of two when compared to the non-tumorous 
surrounding tissue (Fig. 26). Loss of Hippo kinase cascade activity in these tumors was 
substantiated by an almost two-fold increase of YAP nuclear protein extract levels with 
respect to the normal surrounding tissue (Fig. 27). This confirms that cancer cells, 
unlike the surrounding hepatocytes, were still able to enter the cell cycle in response to 
repeated doses of TCPOBOP, presumably they were capable of ‘escaping’ from the 
growth-suppressive environment regulating the growth of normal hepatocytes.
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Fig. 26  Levels of YAP in total protein extracts of the various tumor samples (T) with respect 
to the non-tumorous surrounding liver tissue (S), determined by Western Blot  analysis. Actin 
was used as a loading control. Each lane represents a single sample. Relative expression 
values determined by densitometric analysis are reported under each band.
Fig. 27  Levels of YAP in nuclear protein extracts of the various tumor samples (T) with 
respect to the non-tumorous surrounding liver tissue (S), determined by Western Blot 
analysis. Actin was used as a loading control. Each lane represents a single sample. Relative 
expression values determined by densitometric analysis are reported under each band.
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Previous studies by Dong et al. (2007) identified YAP-induced genes in murine livers 
by microarray  analysis. Among the candidate genes associated with hepatocyte 
proliferation, AFP was classified. qRT-PCR analysis showed that in all (21/21) the 
tumor samples AFP transcript levels were significantly  elevated by a mean fifty-fold 
with respect to those of the non-tumorous surrounding tissue (Fig. 28). Next, another 
direct YAP target gene required for cell growth, CTGF (Zhao et al., 2007; Zhao et al., 
2008; Zhou et al., 2009), a member of the CCN protein family, which causes a variety 
of cellular responses, including reduced cell adhesion and enhanced cell migration and 
proliferation (Brigstock, 1999), was studied in the same tumors. Data obtained showed 
that in nearly  60% (12/21) of the tumor samples, CTGF levels, examined by sqRT-PCR, 
appeared to be higher from the bands intensity, as successively confirmed by 
densitometric analysis (Fig. 29). The latter results further support the fact that in DENA 
+ TCPOBOP-induced carcinogenesis, YAP activity dysregulation contributes to 
uncontrolled hepatocyte proliferation, leading ultimately to such tumor growth. 
Fig. 28  Fold change of AFP mRNA levels of the various tumor samples (T) with respect to 
the non-tumorous surrounding liver tissue (S), determined by  qRT-PCR analysis. GAPDH 
was used as an endogenous normalizer. Results are expressed as means ± SE of three RT-
PCRs per sample. 
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Fig. 29  mRNA levels of CTGF of the various tumor samples (T) with respect to the non-
tumorous surrounding liver tissue (S), determined by sqRT-PCR analysis. 18S was used as 
an internal control. Each lane represents a single sample. Relative expression values 
determined by densitometric analysis are reported under each band.
In recent years, miRNAs have rapidly emerged as important modulators of gene 
expression in cancer (Iorio and Croce, 2009), including human HCC (Ladeiro et al., 
2008; Braconi and Patel, 2008). MiRNAs, are conserved, small (≈ 22 nucleotides), non-
coding RNAs, which by  pairing to complementary binding sites within the 3’ 
untranslated region of hundred of target mRNAs, impair their translation or promote 
their degradation, thus participating in the control of crucial processes, such as 
development, cell proliferation, apoptosis, and differentiation (Ambros, 2004; Bartel, 
2004; Fornari et al., 2010). Signaling pathways (such as the Hippo tumor-suppressor 
pathway) are ideal candidates for miRNA-mediated regulation owing to the sharp  dose-
sensitive nature of their effects (Inui et al., 2010). As a matter of fact, Liu et al. in 2010, 
reported that not only  the YAP oncogene was negatively regulated by miRNA-375 but, 
more crucially, its downregulation was observed in tumor tissue of HCC patients, 
suggesting that YAP is a target of miRNA-375. To verify  these findings in the 
previously  analyzed hepatic tumors, qRT-PCR was performed to assess miRNA-375 
expression. Data obtained demonstrated a significant  decrease in 17 out of 21 tumors 
(81%) when compared to the non-tumorous surrounding tissue. Furthermore, an inverse 
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correlation between miRNA-375 and YAP protein was found in almost 70% (14/21) of 
the analyzed samples (Fig. 30). These results further confirm the involvement of YAP, 
hence the Hippo tumor-suppressor pathway, in DENA + TCPOBOP-induced HCC.
Fig. 30  Fold change of miRNA-375 levels of the various tumor samples (T) with respect to 
the non-tumorous surrounding liver tissue (S), determined by  qRT-PCR analysis. GAPDH 
was used as an endogenous normalizer. Results are expressed as means ± SE of three RT-
PCRs per sample.
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4.4.1 - Hippo and Wnt pathway cooperation in cancer cells arising in hyperplastic livers
Recent reports have suggested that the Hippo signaling pathway networks with other 
well-established pathways, including the Wnt signaling pathway (Sudol and Harvey, 
2010). Wnts consist of a big family  of secreted proteins which act as morphogens to 
control cell fate, differentiation, and proliferation. Wnts bind to cell-surface Frizzled 
(FRZ) and low-density lipoprotein receptor-related protein (LRP) receptors and thereby 
stimulate diverse biological responses (Clevers, 2006; Nusse, 2005). At the core of the 
canonical Wnt pathway is the transcriptional regulator β-catenin. In the absence of Wnt 
stimulation, β-catenin levels are kept  low by proteasome-mediated degradation (Aberle 
et al., 1997). Activation of Wnt signaling induces the hyperphosphorylation of 
Dishevelled (DVL), and this, via a poorly understood mechanism, ultimately  leads to a 
rise in cytoplasmic β-catenin levels, which enables its nuclear translocation and, 
successively, to the activation of β-catenin target genes (Clevers, 2006; Nusse, 2005). 
Varelas et al. (2010), recently  indicated that loss of Hippo pathway activity leads to 
increased nuclear TAZ (the other transcriptional coactivator which, together with YAP, 
is antagonized by the Hippo kinase cascade) and reduces cytoplasmic TAZ-DVL 
binding, hence, causing an increase in Wnt-stimulated DVL phosphorylation, β-catenin 
nuclear accumulation, and, ultimately, induction of Wnt target genes (Fig. 31).
Fig. 31  Hippo kinase cascade-mediated regulation of Wnt signaling pathway via TAZ 
(Varelas et al., 2010).
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a more restricted region along the D/V boundary, was also
increased and extended farther from the D/V boundary in wts
mutant clones (Figure S7B).
Finally, we examined whether the Hpo/Wts target Yki regu-
lates Wg signaling. yki mutant clones are very small, making
analysis of Wg responses difficult. Therefore, we examined Dll
levels in tissues expressing a WT UAS-Yki transgene (Huang
et al., 2005). This revealed that ectopic expression of WT Yki
resulted in decreased expression of the Wg target Dll (Fig-
ure 7C). To assess whether this effect results from the nuclear
Figure 7. The Drosophila Hippo Pathway Inhibits Wingless Signaling
(A)wtsmutant clones have enhanced Arm levels near the D/V boundary in wing imaginal discs. Third-instar wing imaginal discs containingwtsx1 clones, marked
by the absence of GFP, were immunostained with an anti-Arm antibody. A higher-magnification image of the boxed section highlights a clone with enhanced Arm
levels.
(B) The levels of the Wg target, Dll, are enhanced in the outer regions of the wing pouch in wtsmutant clones. Third-instar wing imaginal discs containing wtsx1
clones were immunostained with an anti-Dll antibody. A higher magnification image of the outer wing pouch, a region at which Wg levels are low, highlight the
increased levels of Dll in the absence of wts.
(C) The levels of the Wg target, Dll, are decreased in WT Yki-expressing tissue. Third-instar wing imaginal discs expressing WT Yki were immunostained with an
anti-Dll antibody. A higher-magnification image highlights the decreased levels of Dll.
(D) The levels of the Wg target, Dll, are maintained in Yki-S168A-expressing tissue. Third-instar wing imaginal discs expressing the nuclear-localized Yki-S168A
mutant were immunostained with an anti-Dll antibody. A higher-magnification image highlights the unaltered levels of Dll.
(E) A model for Hippo pathway-mediated inhibition of Wnt signaling via TAZ. The Hippo pathway kinases induce the cytoplasmic localization of TAZ, allowing for
an enhanced interaction between TAZ and DVL. TAZ’s interaction with DVL inhibits CK1d/3 binding andWnt3A-induced DVL phosphorylation, thereby preventing
Wnt3A-induced transcriptional responses. Thus, the Hippo pathway can limit responses to Wnt signals to modulate Wnt-regulated processes.
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Since in the present study  it was demonstrated that cancer cells were still able to 
proliferate in response to repeated stimulus of TCPOBOP, supporting the loss of activity 
of the Hippo tumor-suppressor pathway, levels of β-catenin in total protein extracts of 
hepatic tumors from the 28-week time point of the DENA + TCPOBOP group, were 
analyzed by Western Blot. Densitometric analysis showed that in all (21/21) tumor 
samples, levels of β-catenin almost increased by a mean fold of three, reflecting roughly 
the same trend as that for YAP protein (Fig. 32). Knowing that TAZ is recognized as an 
evolutionarily conserved paralog of YAP, with various similarities, and probably 
subserve separate but perhaps overlapping functions (Kanai et al., 2000), it can be 
assumed that the behavior of YAP, in this case, is identical to that of TAZ. Hence, 
deducing that  Hippo signaling pathway inactivation leads to nuclear translocation of 
YAP, which, after a series of signal transduction cascades, culminates with β-catenin 
nuclear accumulation that successively induces Wnt target genes.
Fig. 32  Levels of β-catenin in total protein extracts of the various tumor samples (T) with 
respect to the non-tumorous surrounding liver tissue (S), determined by Western Blot 
analysis. Actin was used as a loading control. Each lane represents a single sample. Relative 
expression values determined by densitometric analysis are reported under each band.
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Cadoret et al. (2002), indicated that glutamine synthetase (GS), together with two other 
genes, all belonging to the glutamine metabolism pathway, is a transcriptional target of 
β-catenin. Successive studies demonstrated that the same target gene was strongly 
upregulated in tumors exhibiting Ctnnb1 mutations, whereas tumors lacking Ctnnb1 
mutations were negative for GS expression (Loeppen et al., 2002). 
On these bases, in order to evaluate the transcriptional activation of β-catenin in  DENA 
+ TCPOBOP-induced tumors, GS immunohistochemistry was carried out, in the same 
samples analyzed before for β-catenin protein expression. In the normal surrounding 
liver tissue, GS staining was circumscribed to few hepatocytes around the terminal 
central veins, a staining pattern that was first described by Gebhardt  and Mecke (1983). 
On the contrary, the majority  of tumors in these liver sections were GS-positive, with 
most neoplastic lesions showing a relatively homogeneous GS-staining pattern, 
although a heterogeneous expression of GS was also noticed in a small number of 
tumors (Fig. 33).
Fig. 33  Left  Panel: Overview of a liver section from a mouse belonging to the 28-week time 
point of the DENA + TCPOBOP group stained immunohistochemically  for GS. Right 
Panels: Selected area of one of the tumors at higher magnifications (originally x 20 and x 40).
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A more recent study, reported that GS-positive hepatic tumors also exhibited increased 
expression of several CYP isoforms, as a consequence of direct or indirect 
transcriptional activation by β-catenin. Among these genes, Cyp2e1 is of major interest, 
being found, together with Cyp1a, to express more pronounced staining when compared 
to all other isoforms (Loeppen et al., 2005). 
When the same liver sections were stained for Cyp2e1, identical results to those 
obtained with GS staining were observed. In other words, the largest part of the 
neoplastic lesions, unlike the non-tumorous surrounding tissue, stained positively for 
Cyp2e1 (Fig. 34). 
Fig. 34  Left  Panel: Overview of a liver section from a mouse belonging to the 28-week time 
point of the DENA + TCPOBOP group stained immunohistochemically  for Cyp2e1. Right 
Panels: Selected area of one of the tumors at higher magnifications (originally x 20 and x 40).
Since Loeppen et al. in 2002 and 2005, showed that the GS and Cyp2e1 target genes 
were strongly upregulated in tumors exhibiting β-catenin mutations, DENA + 
TCPOBOP-induced tumors, were screened for eventual alterations of Ctnnb1, in the 
same samples analyzed before for the transcriptional activation of β-catenin.
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Primers originally designed by de La Coste et al. (1998) and Devereux et al. (1999), 
and later modified by Aydinlik et al. (2001), utilized to extent the entire region of the 
gene (1473 bp fragment) previously shown to contain deletions of varying length in 
liver tumors, did not detect any  deletions. On the other hand, primers designed by 
Hailfinger et al. (2006) for point mutations at the known hotspots in exon 3 (248 bp 
fragment), showed a prevalence of almost 75% (16/21). Mutations in Ctnnb1 were 
localized at  codons 32, 33, 35, 37 and 41 (first described by Devereux et al., 1999; 
Aydinlik et al., 2001; Strathmann et al., 2006; de La Coste et al., 1998) (Table 5), all of 
which affect, either directly  or indirectly, glycogen synthase kinase 3β (GSK3β)-
mediated phosphorylation. The two types of base substitutions observed were 
transitions from A or T to G or C, respectively (Fig. 35).
Knowing that phosphorylation of β-catenin by GSK3β leads ultimately to β-catenin 
degradation (Willert  and Nusse, 1998; Morin, 1999), hence such mutations augment β-
catenin stability which cause a further increase in cytoplasmic β-catenin levels, 
potentiating the effect of the previously  described YAP-mediated process in hepatic 
tumors. 
β-catenin Mutations
(wildtype sequences of affected codons in parentheses)
Codon 32  (GAT) 33  (TCT) 35  (ATC) 37  (TCT) 41  (ACC)
Mutated 
Sequence GGT CCT/GCT AGC CCT GCC
Number of 
Tumors 2 3/1 6 2 1
Amino Acid 
Change Asp → Gly Ser → Pro/Ala Ile → Ser Ser → Pro Thr → Ala
Table 5  Spectrum of single base substitutions and resulting amino acid changes in liver 
tumors of mice belonging to the 28-week time point of the DENA + TCPOBOP group.
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Fig. 35  Sequence analysis of the various point mutations in the different codons within the 
β-catenin gene in liver tumors of mice belonging to the 28-week time point of the DENA + 
TCPOBOP group.
Aydinlik et al. (2001) demonstrated that rodent liver tumors obtained with a single 
treatment of DENA followed by subsequent chronic administration of phenobarbital, 
according to a classical initiation-promotion experimental protocol, harbored neoplastic 
lesions that predominated in Ctnnb1 mutations and lacked Hras1 mutations. On these 
bases, since DENA + TCPOBOP-induced tumors showed a high prevalence of β-
catenin mutations, a mutation analysis for Ha-ras was carried out.
The sense primer, used for the first time by Buchmann et al. (1991), and antisense 
primer, originally designed by Brown et al. (1990) and later used together by  Jaworski 
et al. (2005), for single base substitutions in codon 61 within coding exon 2 (166 bp 
fragment), did not detect any mutations. This was later confirmed by  analysis of 
appropriate RFLPs (as described by Buchmann et al., 1991 and Bauer-Hofmann et al., 
1992) (Fig. 36). 
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Fig. 36  RFLP analysis of the various single base substitutions in codon 61 within Ha-ras 
gene in hepatic tumors of mice belonging to the 28-week time point of the DENA + 
TCPOBOP group. Hras1 mutations generate new restriction enzyme recognition sites which 
can be detected by  BspHI, TaqI and XbaI enzymes (for mutated sequences CAT, CGA and 
CTA respectively), whereas the mutated sequence AAA leads to the loss of the Hpy188III 
enzyme recognition site. Mutation-specific fragments are marked by a red colored positive 
sign next to the size of the fragment.
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These results confirm that tumors initiated with a single dose of DENA and promoted 
by chronic exposure to a CAR agonist, such as TCPOBOP, present  majorly Ctnnb1 
mutations and lack Hras1 mutations.
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Chapter 5
Conclusions
In conclusion, data obtained from this study clearly demonstrates that in direct 
hyperplasia, achieved by xenobiotic administration, the Hippo pathway  acts as a key 
regulator depending strictly on the organ size. Particularly, the liver becomes rapidly 
refractory to the mitogenic effect of TCPOBOP following repeated administration. 
Remarkably, activation of the Hippo growth-suppressive pathway, thus YAP 
inactivation, being responsible for the homeostatic mechanism triggered to prevent an 
abnormal liver size.
Moreover, data emerged from this study  showed evidently that the same xenobiotic, 
which acts as non-genotoxic liver carcinogen following chronic administration, allow 
‘initiated’ hepatocytes to selectively ‘escape’ from the previously described organ 
constraint, leading ultimately to HCC. Specifically, in TCPOBOP-dependent 
carcinogenesis, DENA-induced mutations are able to continue proliferating in spite of 
repeated administration of the mitogen, thus favoring their clonal expansion. Strikingly, 
dysregulation of the Hippo tumor-suppressive pathway, hence normal YAP activity 
interruption contributes to uncontrolled hepatocyte proliferation, leading ultimately to 
such tumor growth.
Furthermore, data obtained from this study  indicated that Hippo signaling pathway 
inactivation in such tumors leads to nuclear translocation of YAP, which, after a series 
of signal transduction cascades, culminates with β-catenin nuclear accumulation that 
successively induces Wnt target genes. In addition, mutations augment β-catenin 
stability  which cause a further increase in cytoplasmic β-catenin levels, potentiating the 
effect of the previously described YAP-mediated process in hepatic tumors. 
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